PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 32104074-0 2020 CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1. gemcitabine 19-30 Ras association domain family member 1 Homo sapiens 110-116 35421941-10 2022 RESULTS: We observed that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes characterize advanced CML disease and poor imatinib respondents. Imatinib Mesylate 151-159 Ras association domain family member 1 Homo sapiens 80-87 35421941-12 2022 Moreover, we found hypermethylation of p14ARF, RASSF1 and p16INK4A genes and cytokine signalling gene (SOCS1) significantly associated with poor overall survival of CML patients on imatinib therapy. Imatinib Mesylate 181-189 Ras association domain family member 1 Homo sapiens 47-53 35421941-14 2022 CONCLUSION: In this study, we report that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes is a characteristic feature of CML disease progressions, defines poor imatinib respondents and poor overall survival of CML patients to imatinib therapy. Imatinib Mesylate 194-202 Ras association domain family member 1 Homo sapiens 96-103 35421941-14 2022 CONCLUSION: In this study, we report that promoter hydroxymethylation of DAPK1, RIZ1, P16INK4A, RASSF1A and p14ARFARF genes is a characteristic feature of CML disease progressions, defines poor imatinib respondents and poor overall survival of CML patients to imatinib therapy. Imatinib Mesylate 260-268 Ras association domain family member 1 Homo sapiens 96-103 33193895-0 2020 Amide-type local anesthetics may suppress tumor cell proliferation and sensitize Human Hepatocellular Carcinoma Cells to Cisplatin via upregulation of RASSF1A expression and demethylation. Amides 0-5 Ras association domain family member 1 Homo sapiens 151-158 33193895-0 2020 Amide-type local anesthetics may suppress tumor cell proliferation and sensitize Human Hepatocellular Carcinoma Cells to Cisplatin via upregulation of RASSF1A expression and demethylation. Cisplatin 121-130 Ras association domain family member 1 Homo sapiens 151-158 33193895-4 2020 A recent study proved that lidocaine sensitizes breast cancer cells to cisplatin via upregulation of RASSF1A, a promotor of tumor suppressive gene (TSG) demethylation. Lidocaine 27-36 Ras association domain family member 1 Homo sapiens 101-108 33193895-4 2020 A recent study proved that lidocaine sensitizes breast cancer cells to cisplatin via upregulation of RASSF1A, a promotor of tumor suppressive gene (TSG) demethylation. Cisplatin 71-80 Ras association domain family member 1 Homo sapiens 101-108 33193895-11 2020 Lidocaine, ropivacaine and bupivacaine promoted a significant increase in RASSF1A expression and a decrease in RASSF1A methylation. Lidocaine 0-9 Ras association domain family member 1 Homo sapiens 74-81 33193895-11 2020 Lidocaine, ropivacaine and bupivacaine promoted a significant increase in RASSF1A expression and a decrease in RASSF1A methylation. Lidocaine 0-9 Ras association domain family member 1 Homo sapiens 111-118 33193895-11 2020 Lidocaine, ropivacaine and bupivacaine promoted a significant increase in RASSF1A expression and a decrease in RASSF1A methylation. Ropivacaine 11-22 Ras association domain family member 1 Homo sapiens 74-81 33193895-11 2020 Lidocaine, ropivacaine and bupivacaine promoted a significant increase in RASSF1A expression and a decrease in RASSF1A methylation. Ropivacaine 11-22 Ras association domain family member 1 Homo sapiens 111-118 33193895-11 2020 Lidocaine, ropivacaine and bupivacaine promoted a significant increase in RASSF1A expression and a decrease in RASSF1A methylation. Bupivacaine 27-38 Ras association domain family member 1 Homo sapiens 74-81 33193895-11 2020 Lidocaine, ropivacaine and bupivacaine promoted a significant increase in RASSF1A expression and a decrease in RASSF1A methylation. Bupivacaine 27-38 Ras association domain family member 1 Homo sapiens 111-118 33193895-13 2020 Moreover, local anesthetics enhanced the cytotoxicity of cisplatin against HepG2 and BEL-7402 cells, accompanied by an increase in RASSF1A expression. Cisplatin 57-66 Ras association domain family member 1 Homo sapiens 131-138 33193895-15 2020 We also found that these amide local anesthetics may enhance the cytotoxicity of cisplatin in human hepatocellular carcinoma cells possibly via upregulation of RASSF1A expression and demethylation. Amides 25-30 Ras association domain family member 1 Homo sapiens 160-167 33193895-15 2020 We also found that these amide local anesthetics may enhance the cytotoxicity of cisplatin in human hepatocellular carcinoma cells possibly via upregulation of RASSF1A expression and demethylation. Cisplatin 81-90 Ras association domain family member 1 Homo sapiens 160-167 32178333-7 2020 Although the ethanolic extract of propolis (EEP) did not change the global DNA methylation content, by using MS-PCR (Methylation-Specific Polymerase Chain Reaction) we demonstrated that EEP and EGCG were able to partly demethylate the promoter region of RASSF1A in BT-549 cells. epigallocatechin gallate 194-198 Ras association domain family member 1 Homo sapiens 254-261 26121857-1 2015 OBJECTIVE: To explore the effect of demethylating drug 5-Aza-2"-deoxycytidine (5-Aza-CdR) on methtylation status of the Ras-association domain familylA gene (RASSF1A) in human endometrial carcinoma. Decitabine 55-77 Ras association domain family member 1 Homo sapiens 158-165 34402589-0 2021 Low-dose cadmium exposure facilitates cell proliferation by promoter hypermethylation of RASSF1A and DAPK1 genes. Cadmium 9-16 Ras association domain family member 1 Homo sapiens 89-96 34402589-4 2021 Meanwhile, the gene expression of DNA methyltransferases was found to be elevated while that of tumor suppressor genes DAPK1 and RASSF1A were decreased under Cd exposure. Cadmium 158-160 Ras association domain family member 1 Homo sapiens 129-136 34402589-7 2021 Moreover, 5-azacytidine (an inhibitor of DNA methyltransferase) partly impaired Cd-induced promoter hypermethylation of RASSF1A and DAPK1 genes, increased their expressions and slowed down Cd-induced cell proliferation, suggesting that DNA methylation play an essential part in Cd-boosted proliferation. Azacitidine 10-23 Ras association domain family member 1 Homo sapiens 120-127 34402589-7 2021 Moreover, 5-azacytidine (an inhibitor of DNA methyltransferase) partly impaired Cd-induced promoter hypermethylation of RASSF1A and DAPK1 genes, increased their expressions and slowed down Cd-induced cell proliferation, suggesting that DNA methylation play an essential part in Cd-boosted proliferation. Cadmium 80-82 Ras association domain family member 1 Homo sapiens 120-127 34402589-7 2021 Moreover, 5-azacytidine (an inhibitor of DNA methyltransferase) partly impaired Cd-induced promoter hypermethylation of RASSF1A and DAPK1 genes, increased their expressions and slowed down Cd-induced cell proliferation, suggesting that DNA methylation play an essential part in Cd-boosted proliferation. Cadmium 278-280 Ras association domain family member 1 Homo sapiens 120-127 34402589-8 2021 The study showed that Cd caused promoter hypermethylation of RASSF1A and DAPK1, decreasing their expression and leading to higher level of cell proliferation. Cadmium 22-24 Ras association domain family member 1 Homo sapiens 61-68 33786612-0 2021 Dioscin inhibits SCC15 cell proliferation via the RASSF1A/MST2/YAP axis. dioscin 0-7 Ras association domain family member 1 Homo sapiens 50-57 33786612-10 2021 In summary, the results demonstrated that, compared with the control group, dioscin upregulated RASSF1A expression in OSCC cells, which resulted in YAP phosphorylation, thus weakening its transcriptional coactivation function, enhancing cell cycle arrest and apoptosis, and inhibiting cell proliferation. dioscin 76-83 Ras association domain family member 1 Homo sapiens 96-103 33348649-10 2020 Suppression of RASSF1A and subsequent downregulation of DAB2IP enhances GTP loading onto RAS, thus increasing RAS mitogenic signaling in both mutant- and wildtype-RAS cells. Guanosine Triphosphate 72-75 Ras association domain family member 1 Homo sapiens 15-22 32104074-0 2020 CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1. gemcitabine 32-35 Ras association domain family member 1 Homo sapiens 110-116 32104074-13 2020 Conclusion: CircHIPK3 promotes gemcitabine (GEM) resistance in pancreatic cancer cells by targeting RASSF1 via miR-330-5p and regulates proliferation, invasive, migration, EMT, and apoptosis. gemcitabine 31-42 Ras association domain family member 1 Homo sapiens 100-106 32104074-13 2020 Conclusion: CircHIPK3 promotes gemcitabine (GEM) resistance in pancreatic cancer cells by targeting RASSF1 via miR-330-5p and regulates proliferation, invasive, migration, EMT, and apoptosis. gemcitabine 44-47 Ras association domain family member 1 Homo sapiens 100-106 31766357-1 2019 RASSF1 gene methylation predicts longer disease-free survival (DFS) and overall survival (OS) in patients with early-stage non-small-cell lung cancer treated using paclitaxel-based neo-adjuvant chemotherapy compared to patients receiving a gemcitabine-based regimen, according to the randomized Phase 3 IFCT (Intergroupe Francophone de Cancerologie Thoracique)-0002 trial. Paclitaxel 164-174 Ras association domain family member 1 Homo sapiens 0-6 31610501-5 2019 We revealed an increase in global levels of 5-methylcytocine and 5-hydroxymethylcytocine at 10 muM of BPA for 96 h. We observed a significant increase on promoter DNA methylation and decrease on gene expression of p16 gene while no change was observed for Cyclin D2 and Rassf1. gastrofenzin 44-60 Ras association domain family member 1 Homo sapiens 270-276 31766357-1 2019 RASSF1 gene methylation predicts longer disease-free survival (DFS) and overall survival (OS) in patients with early-stage non-small-cell lung cancer treated using paclitaxel-based neo-adjuvant chemotherapy compared to patients receiving a gemcitabine-based regimen, according to the randomized Phase 3 IFCT (Intergroupe Francophone de Cancerologie Thoracique)-0002 trial. gemcitabine 240-251 Ras association domain family member 1 Homo sapiens 0-6 31766357-4 2019 This study reports herein that gemcitabine synergizes with RASSF1A, silencing to increase the IAP-2 expression, which in turn not only interferes with cell proliferation but also promotes cell migration. gemcitabine 31-42 Ras association domain family member 1 Homo sapiens 59-66 31766357-6 2019 Conversely, paclitaxel does not increase the IAP-2 expression but limits the invasiveness of RASSF1A-depleted cells, presumably by rescuing microtubule stabilization. Paclitaxel 12-22 Ras association domain family member 1 Homo sapiens 93-100 31766357-7 2019 Overall, these data provide a functional insight that supports the prognostic value of RASSF1 gene methylation on survival of early-stage lung cancer patients receiving perioperative paclitaxel-based treatment compared to gemcitabine-based treatment, identifying IAP-2 as a novel biomarker indicative of YAP-1-mediated modulation of chemo-sensitivity in lung cancer. Paclitaxel 183-193 Ras association domain family member 1 Homo sapiens 87-93 31933796-0 2019 Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45beta promoter. decitabine 0-10 Ras association domain family member 1 Homo sapiens 94-101 31398393-5 2019 Moreover, the in vitro study demonstrated that high glucose inhibited RASSF1A expression, accompanied by the increases of MeCP2 expression and DNA hypermethylation in RASSF1A promoter region. Glucose 52-59 Ras association domain family member 1 Homo sapiens 70-77 31398393-5 2019 Moreover, the in vitro study demonstrated that high glucose inhibited RASSF1A expression, accompanied by the increases of MeCP2 expression and DNA hypermethylation in RASSF1A promoter region. Glucose 52-59 Ras association domain family member 1 Homo sapiens 167-174 31398393-6 2019 MeCP2 inhibition or knockdown reversed the decrease of RASSF1A transcription induced by high glucose in cardiac fibroblasts. Glucose 93-100 Ras association domain family member 1 Homo sapiens 55-62 31933796-0 2019 Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45beta promoter. gefitinib 20-29 Ras association domain family member 1 Homo sapiens 94-101 31933796-6 2019 Additionally, decitabine, the DNA methyl transferase inhibitor, could reverse the methylation status of RASSF1A and GADD45beta promoters, elevate protein expression, and partially restore the sensitivity of PC9/GR cells to EGFR-TKI. 3-O-methyl-alpha-methyldopamine 34-40 Ras association domain family member 1 Homo sapiens 104-111 31933796-6 2019 Additionally, decitabine, the DNA methyl transferase inhibitor, could reverse the methylation status of RASSF1A and GADD45beta promoters, elevate protein expression, and partially restore the sensitivity of PC9/GR cells to EGFR-TKI. decitabine 14-24 Ras association domain family member 1 Homo sapiens 104-111 31579424-7 2019 Hypermethylation and low expression of RASSF1A gene were detected in PEOC and A2780/DDP. 2-dimethylaminoethyl(dimethylamido)phosphonofluoridate 84-87 Ras association domain family member 1 Homo sapiens 39-46 31623109-0 2019 Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1A. Nitric Oxide 0-12 Ras association domain family member 1 Homo sapiens 109-115 31623109-0 2019 Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1A. DEET 19-23 Ras association domain family member 1 Homo sapiens 109-115 31623109-9 2019 The genes that were upregulated in all four cell lines with DETA/NO were the tumor suppressors Ras association domain family 1 isoform A (RASSF1) and Cyclin-dependent kinase inhibitor 1A (CDKN1A). DEET 60-64 Ras association domain family member 1 Homo sapiens 138-144 31579424-8 2019 Subsequent to being exposed to different concentrations of zebularine-stimulated A2780/DDP, the RASSF1A methylation level was decreased, while the unmethylation level was increased. pyrimidin-2-one beta-ribofuranoside 59-69 Ras association domain family member 1 Homo sapiens 96-103 31579424-8 2019 Subsequent to being exposed to different concentrations of zebularine-stimulated A2780/DDP, the RASSF1A methylation level was decreased, while the unmethylation level was increased. 2-dimethylaminoethyl(dimethylamido)phosphonofluoridate 87-90 Ras association domain family member 1 Homo sapiens 96-103 31547587-0 2019 Activating Hippo Pathway via Rassf1 by Ursolic Acid Suppresses the Tumorigenesis of Gastric Cancer. ursolic acid 39-51 Ras association domain family member 1 Homo sapiens 29-35 31547587-8 2019 Gene ontology analysis revealed that several genes, such as the Hippo pathway upstream target gene, ras association domain family (RASSF1), and its downstream target genes (MST1, MST2, and LATS1) were significantly upregulated by UA, while the expression of YAP1 gene, together with oncogenes (FOXM1, KRAS, and BATF), were significantly decreased. ursolic acid 230-232 Ras association domain family member 1 Homo sapiens 131-137 31547587-9 2019 Similar to the gene expression profiling results, the protein levels of RASSF1, MST1, MST2, LATS1, and p-YAP were increased, whereas those of CTGF were decreased by UA in gastric cancer cells. ursolic acid 165-167 Ras association domain family member 1 Homo sapiens 72-78 31547587-10 2019 The p-YAP expression induced in gastric cancer cells by UA was reversed with RASSF1 silencing. ursolic acid 56-58 Ras association domain family member 1 Homo sapiens 77-83 30371994-4 2018 Methylation-specific PCR was performed on the bisulfite-treated DNA against two tumor suppressor genes;RASSF1A and RB. hydrogen sulfite 46-55 Ras association domain family member 1 Homo sapiens 103-110 31547587-12 2019 Collectively, UA diminishes the proliferation and metastasis of gastric cancer via the regulation of Hippo pathway through Rassf1, which suggests that UA can be used as a potential chemopreventive and therapeutic agent for gastric cancer. ursolic acid 14-16 Ras association domain family member 1 Homo sapiens 123-129 31547587-12 2019 Collectively, UA diminishes the proliferation and metastasis of gastric cancer via the regulation of Hippo pathway through Rassf1, which suggests that UA can be used as a potential chemopreventive and therapeutic agent for gastric cancer. ursolic acid 151-153 Ras association domain family member 1 Homo sapiens 123-129 31500788-7 2019 RASSF1A gene transfected the bladder cancer cells by lipofectamine. Lipofectamine 53-66 Ras association domain family member 1 Homo sapiens 0-7 31062660-7 2019 In vitro induced demethylation with 5-Aza-2"-deoxicytydine (5-Aza-dC) resulted in up-regulation of RASSF1A and an inverse correlation with ANRASSF1 relative abundance in BCCs. 5-aza-2"-deoxicytydine 36-58 Ras association domain family member 1 Homo sapiens 99-106 31062660-7 2019 In vitro induced demethylation with 5-Aza-2"-deoxicytydine (5-Aza-dC) resulted in up-regulation of RASSF1A and an inverse correlation with ANRASSF1 relative abundance in BCCs. Decitabine 60-68 Ras association domain family member 1 Homo sapiens 99-106 30226276-9 2019 The cycloheximide chase assay revealed that RASSF1A expression leads to p53 stabilization and MDM2 homolog degradation. Cycloheximide 4-17 Ras association domain family member 1 Homo sapiens 44-51 31242460-3 2019 Bisulfite pyrosequencing and immunohistochemistry were applied to detect RASSF1A gene methylation and PD-L1 protein expression in tumor cells, respectively. hydrogen sulfite 0-9 Ras association domain family member 1 Homo sapiens 73-80 30082160-9 2018 Data mining study indicated that a trend of increased RASSF1A expression was found in the CRC cell line C2C12 after 5-AZA treatment. Azacitidine 116-121 Ras association domain family member 1 Homo sapiens 54-61 30305100-6 2018 Indeed, the GEF-H1 inactivation induced by RASSF1A silencing, leads to Rab11 accumulation and subsequent exosome releasing, which in turn contribute to TNTs formation. tnts 152-156 Ras association domain family member 1 Homo sapiens 43-50 30305100-8 2018 CONCLUSIONS: This finding suggests for the first time that loss of RASSF1A expression could be a potential biomarker for TNTs formation, such TNTs facilitating intercellular communication favoring multistep progression of bronchial epithelial cells toward overt malignancy. tnts 121-125 Ras association domain family member 1 Homo sapiens 67-74 30305100-8 2018 CONCLUSIONS: This finding suggests for the first time that loss of RASSF1A expression could be a potential biomarker for TNTs formation, such TNTs facilitating intercellular communication favoring multistep progression of bronchial epithelial cells toward overt malignancy. tnts 142-146 Ras association domain family member 1 Homo sapiens 67-74 28871003-5 2017 Promoter methylation of the RASSF1A and O6-methylguanine-DNA-methyltransferase (MGMT) genes was analyzed using bisulfite pyrosequencing of DNA from peripheral blood. hydrogen sulfite 111-120 Ras association domain family member 1 Homo sapiens 28-35 29633080-5 2018 While the DNA methylation levels of CCNA1, RASSF1, and THBS1 were found to be affected by the use of 1% of penicillin/streptomycin in the culture media. Penicillins 107-117 Ras association domain family member 1 Homo sapiens 43-49 29633080-5 2018 While the DNA methylation levels of CCNA1, RASSF1, and THBS1 were found to be affected by the use of 1% of penicillin/streptomycin in the culture media. Streptomycin 118-130 Ras association domain family member 1 Homo sapiens 43-49 29128865-0 2017 Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy. Oxaliplatin 118-129 Ras association domain family member 1 Homo sapiens 24-31 29128865-1 2017 BACKGROUND The purpose of this study was to investigate the prognostic significance of methylation of RAS association domain family protein 1 (RASSF1A) in the promoter region for patients with stage II and III colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy. Oxaliplatin 244-255 Ras association domain family member 1 Homo sapiens 143-150 29128865-10 2017 Cox regression analysis indicated that RASSF1A methylation (HR=2.471, 95% CI=1.125-5.428, p=0.024) and OR (HR=2.678, 95% CI=1.085-6.610, p 0.033) were independently correlated with prognosis for patients treated with oxaliplatin-based chemotherapy. Oxaliplatin 217-228 Ras association domain family member 1 Homo sapiens 39-46 29128865-11 2017 CONCLUSIONS Promoter methylation of RASSF1A can influence sensitivity to oxaliplatin-based chemotherapy, which can be used to predict outcomes for patients with stage II and III CRC. Oxaliplatin 73-84 Ras association domain family member 1 Homo sapiens 36-43 29039788-8 2017 Here, we review the treatment of cancer cells with natural supplements (e.g., methyl donors, vitamins and polyphenols) that have been utilized to revert or prevent the epigenetic silencing of RASSF1A. Polyphenols 106-117 Ras association domain family member 1 Homo sapiens 192-199 29039788-10 2017 Several of these compounds (e.g., reseveratol and curcumin) act by inhibiting the activity or expression of DNA methyltransferases and reactive RASSF1A in cancer. reseveratol 34-45 Ras association domain family member 1 Homo sapiens 144-151 29039788-10 2017 Several of these compounds (e.g., reseveratol and curcumin) act by inhibiting the activity or expression of DNA methyltransferases and reactive RASSF1A in cancer. Curcumin 50-58 Ras association domain family member 1 Homo sapiens 144-151 29368096-0 2018 Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. Decitabine 0-10 Ras association domain family member 1 Homo sapiens 122-129 29368096-0 2018 Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. Cisplatin 36-45 Ras association domain family member 1 Homo sapiens 122-129 29368096-0 2018 Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A. Doxorubicin 50-61 Ras association domain family member 1 Homo sapiens 122-129 29368096-4 2018 Purpose of this study was to observe the effect of combination treatment of decitabine with cisplatin or doxorubicin on bladder cancer cells involving hippo pathway through RASSF1A. Decitabine 76-86 Ras association domain family member 1 Homo sapiens 173-180 29368096-4 2018 Purpose of this study was to observe the effect of combination treatment of decitabine with cisplatin or doxorubicin on bladder cancer cells involving hippo pathway through RASSF1A. Cisplatin 92-101 Ras association domain family member 1 Homo sapiens 173-180 29368096-4 2018 Purpose of this study was to observe the effect of combination treatment of decitabine with cisplatin or doxorubicin on bladder cancer cells involving hippo pathway through RASSF1A. Doxorubicin 105-116 Ras association domain family member 1 Homo sapiens 173-180 29368096-5 2018 Bladder cancer cells (HT1376 & T24) were treated with decitabine and its effect on RASSF1A expression, hippo pathway molecules (MST & YAP), and its downstream targets (CTGF, CYR61 & CTGF) was observed. Decitabine 58-68 Ras association domain family member 1 Homo sapiens 87-94 29368096-7 2018 Decitabine treatment leads to restoration of RASSF1A, activation of hippo pathway followed by decreased expression of its oncogenic downstream targets (CTGF & CYR61). Decitabine 0-10 Ras association domain family member 1 Homo sapiens 45-52 30142219-5 2018 METHODS: DNA yield for use in methylation analysis was determined by quantitative methylation specific PCR (qMSP) targeting the ACTB and RASSF1A genes on bisulfite modified DNA. hydrogen sulfite 154-163 Ras association domain family member 1 Homo sapiens 137-144 29066912-6 2017 The top hub genes AR, CDH13, CDKN2A, DAPK1, GSTP1, CD44 and RASSF1 identified from protein-protein interaction network construction using Search Tool for the Retrieval of Interacting Genes contributed to hormonal response, inflammatory response, cell cycle, reactive oxygen species activity and receptor kinase activity, which are related to hallmarks of cancer as revealed by their functional enrichment analysis by Cytoscape. Reactive Oxygen Species 258-281 Ras association domain family member 1 Homo sapiens 60-66 28938637-7 2017 The treatment of 5-Aza-CR or knockdown of DNMT1 in vitro could inhibit the expressions of DNMT1 but restore the TSGs expressions including the Ras association domain family 1A (RASSF1A) and the adenomatous polyposis coli (APC) via the demethylation of its promoter region, which results in the decreased proliferation, increased apoptosis and impaired ability of migration. Azacitidine 17-25 Ras association domain family member 1 Homo sapiens 143-175 28838380-13 2017 Aberrant methylation of RASSF1A has been reported in various tumours, but this is the first report of RASSF1A hypermethylation in TETs. Tetramine 130-134 Ras association domain family member 1 Homo sapiens 102-109 28938637-7 2017 The treatment of 5-Aza-CR or knockdown of DNMT1 in vitro could inhibit the expressions of DNMT1 but restore the TSGs expressions including the Ras association domain family 1A (RASSF1A) and the adenomatous polyposis coli (APC) via the demethylation of its promoter region, which results in the decreased proliferation, increased apoptosis and impaired ability of migration. Azacitidine 17-25 Ras association domain family member 1 Homo sapiens 177-184 28592103-10 2017 DNA methylation levels of P16, RASSF1A and MGMT were 2.04+-0.41, 2.19 (1.94-2.51), 2.22 (1.94-2.46)%5mC in exposure group, and 2.19+-0.40, 2.41 (2.11-2.67), 2.44 (2.15-2.91)%5mC in control group. 5-Methylcytosine 100-103 Ras association domain family member 1 Homo sapiens 31-38 28670882-3 2017 Objective: Toexamine the role of circulating RASSF1A as a non-invasive diagnostic marker for HCC. toexamine 11-20 Ras association domain family member 1 Homo sapiens 45-52 27864689-5 2017 MTX-BLPD patients without hypermethylated RAS-associated domain family-1A (RASSF1A) or O 6 -methyl guanine-DNA methyltransferase (MGMT) had significantly better prognosis than those with hypermethylation of those genes (P = 0.033). Methotrexate 0-3 Ras association domain family member 1 Homo sapiens 42-73 28350046-0 2017 [Corrigendum] Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. Docetaxel 102-111 Ras association domain family member 1 Homo sapiens 38-45 28435431-0 2017 Dioscin induces demethylation of DAPK-1 and RASSF-1alpha genes via the antioxidant capacity, resulting in apoptosis of bladder cancer T24 cells. dioscin 0-7 Ras association domain family member 1 Homo sapiens 44-56 28435431-5 2017 Further, we examined the ability of dioscin, a natural antioxidant, to regulate methylation status and expression of DAPK-1 and RASSF-1alpha genes in BC cell lines. dioscin 36-43 Ras association domain family member 1 Homo sapiens 128-140 28435431-8 2017 Dioscin triggered demethylation of DAPK1 and RASSF-1alpha genes in T24 cells and increased the gene and protein expression in 5637 and T24 cells. dioscin 0-7 Ras association domain family member 1 Homo sapiens 45-57 28435431-12 2017 Collectively, dioscin induces demethylation of DAPK-1 and RASSF-1alpha genes via the antioxidant capacity, resulting in apoptosis of bladder cancer T24 cells or inhibitory cell viability. dioscin 14-21 Ras association domain family member 1 Homo sapiens 58-70 28069272-15 2017 Regarding DNA methylation, all four SMARCB1/INI1-deficient tumors showed methylation of RASSF1 gene by means of MS-MLPA. ms-mlpa 112-119 Ras association domain family member 1 Homo sapiens 88-94 27864689-5 2017 MTX-BLPD patients without hypermethylated RAS-associated domain family-1A (RASSF1A) or O 6 -methyl guanine-DNA methyltransferase (MGMT) had significantly better prognosis than those with hypermethylation of those genes (P = 0.033). Methotrexate 0-3 Ras association domain family member 1 Homo sapiens 75-82 27818231-0 2016 Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells. phenethyl isothiocyanate 38-62 Ras association domain family member 1 Homo sapiens 27-34 27818231-0 2016 Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells. phenethyl isothiocyanate 64-69 Ras association domain family member 1 Homo sapiens 27-34 27818231-14 2016 The function of RASSF1A reactivation in promoting apoptosis and inducing G2/M cell cycle arrest was analyzed using flow-cytometry analysis with Annexin V and propidium iodide (PI). Propidium 158-174 Ras association domain family member 1 Homo sapiens 16-23 27818231-21 2016 Collectively, the results of our study suggest that PEITC induces apoptosis in LNCaP cells potentially by reactivating RASSF1A via epigenetic mechanisms. phenethyl isothiocyanate 52-57 Ras association domain family member 1 Homo sapiens 119-126 26410583-7 2016 In all study subjects and non-smoking workers, increasing quartiles of urinary summed OH-PAHs was associated with hypomethylation of p16, RASSF1A, and MGMT (all p < 0.05). oh-pahs 86-93 Ras association domain family member 1 Homo sapiens 138-145 27384977-0 2016 miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. mir-181a 0-8 Ras association domain family member 1 Homo sapiens 98-104 27384977-0 2016 miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Sorafenib 17-26 Ras association domain family member 1 Homo sapiens 98-104 27384977-8 2016 In addition, we demonstrated that miR-181a directly targets RASSF1, a MAPK signaling factor, and knockdown of RASSF1 increased sorafenib resistance. Sorafenib 127-136 Ras association domain family member 1 Homo sapiens 60-66 27384977-8 2016 In addition, we demonstrated that miR-181a directly targets RASSF1, a MAPK signaling factor, and knockdown of RASSF1 increased sorafenib resistance. Sorafenib 127-136 Ras association domain family member 1 Homo sapiens 110-116 27384977-9 2016 Taken together, these results suggest that miR-181a provokes sorafenib resistance through suppression of RASSF1. Sorafenib 61-70 Ras association domain family member 1 Homo sapiens 105-111 27600004-4 2016 The specific binding ability of miR-181a to RASSF1A 3"-UTR was theoretically predicted and detected by the dual luciferase reporter gene assay. mir-181a 32-40 Ras association domain family member 1 Homo sapiens 44-51 26894600-0 2016 Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia. Valproic Acid 0-13 Ras association domain family member 1 Homo sapiens 54-61 26935905-10 2016 miR-181b achieved the tumor suppressive effects via direct targeting of the RASSF1A gene. mir-181b 0-8 Ras association domain family member 1 Homo sapiens 76-83 27347211-10 2016 The frequency of RASSF1A methylation in patients with oCRC was 25%. ocrc 54-58 Ras association domain family member 1 Homo sapiens 17-24 27042241-14 2016 As a proof of principle, there was concordance in the kinetics of the RASSF1A and the serological cancer biomarkers CA 15-3, CEA, and TPA. Tetradecanoylphorbol Acetate 134-137 Ras association domain family member 1 Homo sapiens 70-77 26825171-3 2016 Direct interaction between the C-terminal amino acids (256-277) of RASSF1A and active GTP-RhoA was critical for this antagonism. Guanosine Triphosphate 86-89 Ras association domain family member 1 Homo sapiens 67-74 26825171-4 2016 In addition, interaction between the N-terminal amino acids (69-82) of RASSF1A and the ubiquitin E3 ligase Smad ubiquitination regulatory factor 1 (Smurf1) disrupted GTPase activity by facilitating Smurf1-mediated ubiquitination of GTP-RhoA. Guanosine Triphosphate 166-169 Ras association domain family member 1 Homo sapiens 71-78 26562330-0 2016 Femtomolar level detection of RASSF1A tumor suppressor gene methylation by electrochemical nano-genosensor based on Fe3O4/TMC/Au nanocomposite and PT-modified electrode. ferryl iron 116-121 Ras association domain family member 1 Homo sapiens 30-37 26759237-5 2016 Mechanistic investigations revealed that RASSF1A blocked tumor growth by stimulating cofilin/PP2A-mediated dephosphorylation of the guanine nucleotide exchange factor GEF-H1, thereby stimulating its ability to activate the antimetastatic small GTPase RhoB. Guanine Nucleotides 132-150 Ras association domain family member 1 Homo sapiens 41-48 26562330-0 2016 Femtomolar level detection of RASSF1A tumor suppressor gene methylation by electrochemical nano-genosensor based on Fe3O4/TMC/Au nanocomposite and PT-modified electrode. trimethylchlorosilane 122-125 Ras association domain family member 1 Homo sapiens 30-37 26562330-0 2016 Femtomolar level detection of RASSF1A tumor suppressor gene methylation by electrochemical nano-genosensor based on Fe3O4/TMC/Au nanocomposite and PT-modified electrode. Gold 126-128 Ras association domain family member 1 Homo sapiens 30-37 25483734-7 2015 When SNU-719, MKN-28 and AGS cells were treated with the demethylating agent 5-aza-2"-deoxycytidine, RASSF1A gene expression was restored and the methylation-specific polymerase chain reaction pattern was altered in all three cell lines. 4-(1H-Pyrrol-1-yl)aniline 5-8 Ras association domain family member 1 Homo sapiens 101-108 26482848-4 2015 Using peptide mass fingerprinting, we identified protein arginine N-methyltransferase 5 (PRMT5), a type II protein arginine N-methyltransferase that monomethylates and symmetrically dimethylates arginine residues, as a novel protein that interacts with RASSF1A. Arginine 57-65 Ras association domain family member 1 Homo sapiens 253-260 26587041-5 2015 RESULTS: It was found that the frequency of the RASSF1A Ala133Ser T allele (Ala/Ser and Ser/Ser) genotype in HCC cases was observably higher than that of normal subjects (P < 0.001). Alanine 56-59 Ras association domain family member 1 Homo sapiens 48-55 26587041-5 2015 RESULTS: It was found that the frequency of the RASSF1A Ala133Ser T allele (Ala/Ser and Ser/Ser) genotype in HCC cases was observably higher than that of normal subjects (P < 0.001). Serine 62-65 Ras association domain family member 1 Homo sapiens 48-55 26587041-5 2015 RESULTS: It was found that the frequency of the RASSF1A Ala133Ser T allele (Ala/Ser and Ser/Ser) genotype in HCC cases was observably higher than that of normal subjects (P < 0.001). Serine 80-83 Ras association domain family member 1 Homo sapiens 48-55 26587041-5 2015 RESULTS: It was found that the frequency of the RASSF1A Ala133Ser T allele (Ala/Ser and Ser/Ser) genotype in HCC cases was observably higher than that of normal subjects (P < 0.001). Serine 80-83 Ras association domain family member 1 Homo sapiens 48-55 24748501-5 2015 METHODS: The methylation status of five DNA damage repair genes (CHFR, FANCF, MGMT, MLH1, and RASSF1A) was detected by nested methylation-specific PCR in 102 paraffin-embedded gastric cancer samples. Paraffin 158-166 Ras association domain family member 1 Homo sapiens 94-101 25805039-0 2015 Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients. Folic Acid 15-21 Ras association domain family member 1 Homo sapiens 125-132 25805039-0 2015 Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients. Carbon 36-42 Ras association domain family member 1 Homo sapiens 125-132 25483734-7 2015 When SNU-719, MKN-28 and AGS cells were treated with the demethylating agent 5-aza-2"-deoxycytidine, RASSF1A gene expression was restored and the methylation-specific polymerase chain reaction pattern was altered in all three cell lines. Decitabine 77-99 Ras association domain family member 1 Homo sapiens 101-108 25392149-9 2015 The UVB-induced DNA hypermethylation of P16 and RASSF1A and subsequent gene silencing was reversed by PCF treatment. PHENYL CHLOROFORMATE 102-105 Ras association domain family member 1 Homo sapiens 48-55 25922721-4 2015 DNA samples were extracted from biopsy tissues, serum and plasma and QMSP of APC and RASSF1A was carried out after bisulfite conversion. hydrogen sulfite 115-124 Ras association domain family member 1 Homo sapiens 85-92 25330645-0 2014 [Effects of arsenic trioxide combined with cisplatin on the growth of human nasopharyngeal carcinoma cells and reversion of RASSF1A hympermethylation]. Arsenic Trioxide 12-28 Ras association domain family member 1 Homo sapiens 124-131 25087768-9 2014 Furthermore selenite, but not MSA, markedly induced (P<0.05) cytotoxicity and increased (P<0.05) RASSF1A expression. Selenious Acid 12-20 Ras association domain family member 1 Homo sapiens 103-110 25526566-0 2014 Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARbeta2 and RASSF1A demethylation. Lidocaine 0-9 Ras association domain family member 1 Homo sapiens 108-115 25526566-0 2014 Lidocaine sensitizes the cytotoxicity of cisplatin in breast cancer cells via up-regulation of RARbeta2 and RASSF1A demethylation. Cisplatin 41-50 Ras association domain family member 1 Homo sapiens 108-115 25526566-4 2014 Results demonstrated that lidocaine promoted a significant global genomic demethylation, and particularly in the promoters of tumor suppressive genes (TSGs), RARbeta2 and RASSF1A. Lidocaine 26-35 Ras association domain family member 1 Homo sapiens 171-178 25526566-8 2014 In conclusion, the present study confirms the demethylation effect of lidocaine in breast cancer cells, and found that the demethylation of RARbeta2 and RASSF1A sensitized the cytotoxicity of cisplatin in breast cancer cells. Cisplatin 192-201 Ras association domain family member 1 Homo sapiens 153-160 25316809-6 2014 Pyrosequencing analyses confirmed that SGI-110 caused both global (LINE1) and gene-specific hypomethylation in vivo, including TSGs (RASSF1A), proposed drivers of ovarian cancer cisplatin resistance (MLH1 and ZIC1), differentiation-associated genes (HOXA10 and HOXA11), and transcription factors (STAT5B). Cisplatin 178-187 Ras association domain family member 1 Homo sapiens 133-140 24945829-8 2014 5-AzadC also prevented the loss of RASSF1A expression that occurs during activated cardiac fibroblasts. Decitabine 0-7 Ras association domain family member 1 Homo sapiens 35-42 25330645-9 2014 As2O3 inhibits the malignant phenotypes of human nasopharyngeal carcinoma cells and reverses hypermethylation of RASSF1A. Arsenic Trioxide 0-5 Ras association domain family member 1 Homo sapiens 113-120 23934182-2 2014 To demonstrate this hypothesis, we have treated MCF-7 and MDA-MB-231 cells with different doses of homocysteine and observed dose-dependent inhibition of BRCA1 and RASSF1, respectively. Homocysteine 99-111 Ras association domain family member 1 Homo sapiens 164-170 24756244-4 2014 Frequent silencing of RASSF1A but not RASSF1B and RASSF1C were found in esophageal cancer cell lines and the silencing of RASSF1A may be reversed by 5-Aza-dC treatment. Azacitidine 149-154 Ras association domain family member 1 Homo sapiens 22-29 24756244-4 2014 Frequent silencing of RASSF1A but not RASSF1B and RASSF1C were found in esophageal cancer cell lines and the silencing of RASSF1A may be reversed by 5-Aza-dC treatment. Azacitidine 149-154 Ras association domain family member 1 Homo sapiens 122-129 24534923-9 2014 Select results were confirmed by quantitative real-time PCR demonstrating that beta-D-glucan increased RASSF1 expression in MCF-7 cells and IGFBP3, CTNNB1 and ERbeta transcript expression in LCC9 cells. maltotriose 79-92 Ras association domain family member 1 Homo sapiens 103-109 23934182-5 2014 Peripheral blood CpG island methylation of BRCA1 in all types of breast cancer and methylation of RASSF1 in ER/PR-negative breast cancers showed positive correlation with total plasma homocysteine. Homocysteine 184-196 Ras association domain family member 1 Homo sapiens 98-104 23934182-12 2014 To conclude, elevated homocysteine influences methionine dependency phenotype of breast cancer cells and is associated with breast cancer progression by epigenetic modulation of RASSF1 and BRCA1. Homocysteine 22-34 Ras association domain family member 1 Homo sapiens 178-184 25764814-3 2014 Only 1 subject (2.1%) from the control group (healthy young individuals, age <= 35) has methylation of the studied CpG--dinucleotides of RASSF1A gene. cytidylyl-3'-5'-guanosine 118-136 Ras association domain family member 1 Homo sapiens 140-147 23934182-1 2014 Our recent study showing association of hyperhomocysteinemia and hypomethioninemia in breast cancer and other studies indicating association of hyperhomocysteinemia with metastasis and development of drug resistance in breast cancer cells treated with homocysteine lead us to hypothesize that homocysteine might modulate the expression of certain tumor suppressors, i.e., RASSF1, RARbeta1, CNND1, BRCA1, and p21, and might influence prognostic markers such as BNIP3 by inducing epigenetic alteration. Homocysteine 149-161 Ras association domain family member 1 Homo sapiens 372-378 24870779-7 2014 Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, Pheterogeneity=0.75). Serine 96-99 Ras association domain family member 1 Homo sapiens 82-89 24870779-7 2014 Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, Pheterogeneity=0.75). Alanine 90-93 Ras association domain family member 1 Homo sapiens 82-89 24870779-7 2014 Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, Pheterogeneity=0.75). Serine 145-148 Ras association domain family member 1 Homo sapiens 82-89 24870779-7 2014 Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, Pheterogeneity=0.75). Serine 145-148 Ras association domain family member 1 Homo sapiens 82-89 24870779-7 2014 Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, Pheterogeneity=0.75). Alanine 152-155 Ras association domain family member 1 Homo sapiens 82-89 24870779-7 2014 Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, Pheterogeneity=0.75). Serine 145-148 Ras association domain family member 1 Homo sapiens 82-89 24870779-7 2014 Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, Pheterogeneity=0.75). Alanine 152-155 Ras association domain family member 1 Homo sapiens 82-89 24870779-7 2014 Moreover, in subgroup analyses by cancer types, a significant association between RASSF1A Ala133Ser polymorphism and lung cancer risk was found (Ser vs Ala: OR=2.27, 95% CI=1.29-4.02, Pheterogeneity=0.61; Ser/Ser+Ala/ Ser vs Ala/Ala: OR=2.42, 95% CI=1.33-4.42, Pheterogeneity=0.75). Alanine 152-155 Ras association domain family member 1 Homo sapiens 82-89 24870779-8 2014 In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity<=0.001). Serine 84-87 Ras association domain family member 1 Homo sapiens 70-77 24870779-8 2014 In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity<=0.001). Alanine 78-81 Ras association domain family member 1 Homo sapiens 70-77 24870779-8 2014 In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity<=0.001). Serine 152-155 Ras association domain family member 1 Homo sapiens 70-77 24870779-8 2014 In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity<=0.001). Serine 152-155 Ras association domain family member 1 Homo sapiens 70-77 24870779-8 2014 In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity<=0.001). Alanine 159-162 Ras association domain family member 1 Homo sapiens 70-77 24870779-8 2014 In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity<=0.001). Serine 152-155 Ras association domain family member 1 Homo sapiens 70-77 24870779-8 2014 In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity<=0.001). Alanine 159-162 Ras association domain family member 1 Homo sapiens 70-77 24870779-8 2014 In addition, in subgroup analyses by ethnicity, it was found that the RASSF1A Ala133Ser polymorphism was associated with overall cancer risk in Asians (Ser vs Ala: OR=1.37, 95% CI=1.06-1.77, Pheterogeneity=0.06) and Caucasians (Ser/Ser+Ala/Ser vs Ala/Ala: OR=2.21, 95% CI=1.01-4.82, Pheterogeneity<=0.001). Alanine 159-162 Ras association domain family member 1 Homo sapiens 70-77 24634863-0 2014 5-Aza-2""-deoxycytidine inhibits retinoblastoma cell by reactivating epigenetically silenced RASSF1A gene. Decitabine 0-23 Ras association domain family member 1 Homo sapiens 93-100 24391879-4 2013 In this study, we have used PAP in combination with bisulfite conversion to develop a new universal methylation-based assay for the detection of fetal methylated RASSF1A sequences in maternal plasma. hydrogen sulfite 52-61 Ras association domain family member 1 Homo sapiens 162-169 24447120-1 2014 We reported that resveratrol decreased DNA methyltransferase (DNMT) 1 and 3b expression in vitro and demethylates tumor suppressor RASSF-1a in women at increased breast cancer risk. Resveratrol 17-28 Ras association domain family member 1 Homo sapiens 131-139 24197116-4 2014 Using tandem mass spectrometry and biochemical analysis, it was determined that CHK1 phosphorylates RASSF1A on Serine 184, which has been shown to be mutated in a subset of human primary nasopharyngeal carcinomas. Serine 111-117 Ras association domain family member 1 Homo sapiens 100-107 24197116-5 2014 Furthermore, Serine 184 phosphorylation of RASSF1A was significantly diminished by a CHK1-specific kinase inhibitor. Serine 13-19 Ras association domain family member 1 Homo sapiens 43-50 24197116-9 2014 IMPLICATIONS: This study reveals that CHK1-mediated phosphorylation of RASSF1A, at Serine 184, plays an important role in cell-cycle regulation and highlights that mutation of this CHK1 phosphorylation site in nasopharyngeal carcinoma has disease relevance. Serine 83-89 Ras association domain family member 1 Homo sapiens 71-78 24391879-6 2013 Methylation specific primers for PAP were designed for the detection of fetal methylated RASSF1A sequences after bisulfite conversion and validated. hydrogen sulfite 113-122 Ras association domain family member 1 Homo sapiens 89-96 23864847-10 2013 The restoration of RASSF1A by 5-Aza-dC treatment also induced acetylated alpha-tubulin through inhibition of HDAC6 activity that finally resulted in suppressing cell migration in H1299 cells. Decitabine 30-38 Ras association domain family member 1 Homo sapiens 19-26 24004978-3 2013 We applied this method to introduce methylated cytosines into fragments of the respective DAPK and RASSF1A promoters that had been cloned into luciferase reporters. Cytosine 47-56 Ras association domain family member 1 Homo sapiens 99-106 23989600-5 2013 We examined the methylation status of the RASSF1A promoter region by bisulfite pyrosequencing. hydrogen sulfite 69-78 Ras association domain family member 1 Homo sapiens 42-49 24001151-4 2013 RESULTS: Using methylation-specific PCR we establish that mahanine restores the expression of RASSF1A by inducing the demethylation of its promoter in prostate cancer cells. mahanine 58-66 Ras association domain family member 1 Homo sapiens 94-101 24001151-9 2013 CONCLUSIONS: Taken together, we show that mahanine treatment induces the proteasomal degradation of DNMT1 and DNMT3B via the inactivation of Akt, which facilitates the demethylation of the RASSF1A promoter and restores its expression in prostate cancer cells. mahanine 42-50 Ras association domain family member 1 Homo sapiens 189-196 23104224-6 2012 RASSF1, SCGB3A1 and SFRP5 had significant higher methylation levels in CCL compared to normal breast tissue, but showed no significant differences between CCL, DCIS and invasive carcinoma. Cefaclor 71-74 Ras association domain family member 1 Homo sapiens 0-6 23898615-6 2013 RESULT: As2O3 group and AS2O3 + DDP group could obviously inhibit the growth of tumor, induce the apoptosis of human naso pharyngeal carcinoma cell and up-regulate the expression of RASSF1A. Arsenic Trioxide 8-13 Ras association domain family member 1 Homo sapiens 182-189 23898615-6 2013 RESULT: As2O3 group and AS2O3 + DDP group could obviously inhibit the growth of tumor, induce the apoptosis of human naso pharyngeal carcinoma cell and up-regulate the expression of RASSF1A. Arsenic Trioxide 24-29 Ras association domain family member 1 Homo sapiens 182-189 23579583-8 2013 Circulating hypermethylated RASSF1A levels in maternal plasma related to total bile acid. Bile Acids and Salts 79-88 Ras association domain family member 1 Homo sapiens 28-35 24216995-6 2013 Proteins from the Ras association family (Rassf, especially Rassf1 and Rassf5) are tumor suppressors that are activated by Ras-GTP, triggering apoptosis via e.g., activation of mammalian sterile 20-like (MST1) kinase. ras-gtp 123-130 Ras association domain family member 1 Homo sapiens 42-47 24216995-6 2013 Proteins from the Ras association family (Rassf, especially Rassf1 and Rassf5) are tumor suppressors that are activated by Ras-GTP, triggering apoptosis via e.g., activation of mammalian sterile 20-like (MST1) kinase. ras-gtp 123-130 Ras association domain family member 1 Homo sapiens 60-66 23294242-1 2013 The Ras association domain family (Rassf) is one of the Ras effectors, which can bind to several GTP-charged Ras-like GTPases. Guanosine Triphosphate 97-100 Ras association domain family member 1 Homo sapiens 35-40 22389451-2 2012 A single-nucleotide polymorphism located in the region of the key ATM activation site of RASSF1A predicts the conversion of alanine (encoded by the major G allele) to serine (encoded by the minor T allele) at residue 133 of RASSF1A (p.Ala133Ser). Alanine 124-131 Ras association domain family member 1 Homo sapiens 89-96 22172412-0 2012 RASSF1A hypermethylation is associated with aflatoxin B1 and polycyclic aromatic hydrocarbon exposure in hepatocellular carcinoma. Aflatoxin B1 44-56 Ras association domain family member 1 Homo sapiens 0-7 22172412-0 2012 RASSF1A hypermethylation is associated with aflatoxin B1 and polycyclic aromatic hydrocarbon exposure in hepatocellular carcinoma. Polycyclic Aromatic Hydrocarbons 61-92 Ras association domain family member 1 Homo sapiens 0-7 22172412-5 2012 Multivariate analysis indicated that RASSF1A hypermethylation was related to AFB1- (p=0.046) and PAH-DNA adducts (p=0.040). Polycyclic Aromatic Hydrocarbons 97-100 Ras association domain family member 1 Homo sapiens 37-44 22172412-8 2012 CONCLUSIONS: AFB1- and PAH-DNA adducts may be associated with RASSF1A hypermethylation in hepatocarcinogenesis. Polycyclic Aromatic Hydrocarbons 23-26 Ras association domain family member 1 Homo sapiens 62-69 22581300-0 2012 Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. Docetaxel 100-109 Ras association domain family member 1 Homo sapiens 24-31 22581300-3 2012 Therefore, the potential associations of RASSF1A hypermethylation and response to docetaxel-based chemotherapy were evaluated, and the underlying mechanism was studied. Docetaxel 94-103 Ras association domain family member 1 Homo sapiens 41-48 22581300-7 2012 Finally, in vitro studies showed that RASSF1A had cooperative activity in suppression of cancer cell growth and proliferation by enhancing docetaxel-induced cell cycle arrest. Docetaxel 163-172 Ras association domain family member 1 Homo sapiens 50-57 22581300-8 2012 Our results suggest that hypermethylated RASSF1A is an important modulating factor for the efficacy of docetaxel-based chemotherapy in breast cancer. Docetaxel 115-124 Ras association domain family member 1 Homo sapiens 41-48 22382007-10 2012 RESULTS: RASSF1A promoter hypermethylation was detected in 33.6% of BCs and occurred more frequently in MIBC (46.1%) than in NMIBC (25.8%) (P < .001). 4-METHYL-2-PENTANOL 104-108 Ras association domain family member 1 Homo sapiens 9-16 22434665-8 2012 In addition, RASSF1A methylation predicted longer DFS in patients treated with paclitaxel-carboplatin compared with gemcitabine-cisplatin (adjusted HR = 0.47, 95% CI: 0.23-0.97, P(interaction) = 0.042). Paclitaxel 79-89 Ras association domain family member 1 Homo sapiens 13-20 22434665-8 2012 In addition, RASSF1A methylation predicted longer DFS in patients treated with paclitaxel-carboplatin compared with gemcitabine-cisplatin (adjusted HR = 0.47, 95% CI: 0.23-0.97, P(interaction) = 0.042). Carboplatin 90-101 Ras association domain family member 1 Homo sapiens 13-20 22434665-8 2012 In addition, RASSF1A methylation predicted longer DFS in patients treated with paclitaxel-carboplatin compared with gemcitabine-cisplatin (adjusted HR = 0.47, 95% CI: 0.23-0.97, P(interaction) = 0.042). gemcitabine 116-127 Ras association domain family member 1 Homo sapiens 13-20 22434665-11 2012 Conversely, significantly longer DFS following paclitaxel-based neoadjuvant chemotherapy for patients whose tumors showed RASSF1A methylation suggested its predictive interest in stages I and II NSCLC. Paclitaxel 47-57 Ras association domain family member 1 Homo sapiens 122-129 22520501-9 2012 Three common polymorphisms in the RASSF1A gene, 133Ala/Ser (G/T), -710C/T and -392C/T, were genotyped using TaqMan assays and haplotypes were analysed using appropriate software. Serine 55-58 Ras association domain family member 1 Homo sapiens 34-41 22389451-2 2012 A single-nucleotide polymorphism located in the region of the key ATM activation site of RASSF1A predicts the conversion of alanine (encoded by the major G allele) to serine (encoded by the minor T allele) at residue 133 of RASSF1A (p.Ala133Ser). Alanine 124-131 Ras association domain family member 1 Homo sapiens 224-231 22389451-2 2012 A single-nucleotide polymorphism located in the region of the key ATM activation site of RASSF1A predicts the conversion of alanine (encoded by the major G allele) to serine (encoded by the minor T allele) at residue 133 of RASSF1A (p.Ala133Ser). Serine 167-173 Ras association domain family member 1 Homo sapiens 89-96 22389451-2 2012 A single-nucleotide polymorphism located in the region of the key ATM activation site of RASSF1A predicts the conversion of alanine (encoded by the major G allele) to serine (encoded by the minor T allele) at residue 133 of RASSF1A (p.Ala133Ser). Serine 167-173 Ras association domain family member 1 Homo sapiens 224-231 22389451-3 2012 Secondary protein structure prediction studies suggest that an alpha helix containing the ATM recognition site is disrupted in the serine isoform of RASSF1A (RASSF1A-p.133Ser). Serine 131-137 Ras association domain family member 1 Homo sapiens 149-156 22389451-3 2012 Secondary protein structure prediction studies suggest that an alpha helix containing the ATM recognition site is disrupted in the serine isoform of RASSF1A (RASSF1A-p.133Ser). Serine 131-137 Ras association domain family member 1 Homo sapiens 158-165 22332908-7 2012 RASSF-1alpha methylation decreased with increasing levels of serum trans-resveratrol (P = .047). Resveratrol 67-84 Ras association domain family member 1 Homo sapiens 0-12 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Guanine 2-9 Ras association domain family member 1 Homo sapiens 104-111 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Guanine 2-9 Ras association domain family member 1 Homo sapiens 258-265 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Alanine 131-138 Ras association domain family member 1 Homo sapiens 104-111 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Alanine 131-138 Ras association domain family member 1 Homo sapiens 258-265 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Alanine 140-143 Ras association domain family member 1 Homo sapiens 104-111 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Alanine 140-143 Ras association domain family member 1 Homo sapiens 258-265 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Serine 148-154 Ras association domain family member 1 Homo sapiens 104-111 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Serine 148-154 Ras association domain family member 1 Homo sapiens 258-265 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Serine 156-159 Ras association domain family member 1 Homo sapiens 104-111 22394463-2 2012 A guanine (G)/thymine (T) common single nucleotide polymorphism (SNP) at first position of codon 133 in RASSF1A gene determines an alanine (Ala) to serine (Ser) (Ala133Ser) amino acidic substitution which may alter cancer risk by influencing the function of RASSF1A protein. Serine 156-159 Ras association domain family member 1 Homo sapiens 258-265 22332908-8 2012 The change in RASSF-1alpha methylation was directly related to the change in PGE(2) (P = .045). Dinoprostone 77-83 Ras association domain family member 1 Homo sapiens 14-26 22332908-9 2012 This work provides novel insights into the effects of trans-resveratrol on the breast of women at increased breast cancer risk, including a decrease in methylation of the tumor suppressor gene RASSF-1alpha. Resveratrol 54-71 Ras association domain family member 1 Homo sapiens 193-205 21643015-0 2012 Regulation of mitosis and taxane response by Daxx and Rassf1. taxane 26-32 Ras association domain family member 1 Homo sapiens 54-60 22246327-15 2012 5-Aza application resulted in partial demethylation of the MGMT and RASSF1A TSGs and reduced proliferation of the tumor cells suggesting further evaluation of 5-Aza for HNSCC treatment. Azacitidine 0-5 Ras association domain family member 1 Homo sapiens 80-87 21643015-7 2012 These data suggest that Daxx and Rassf1 define a mitotic stress checkpoint that enables cells to exit mitosis as micronucleated cells (and eventually die) when encountered with specific mitotic stress stimuli, including taxol. Paclitaxel 220-225 Ras association domain family member 1 Homo sapiens 33-39 21643015-9 2012 Daxx and Rassf1 may become useful predictive markers for the proper selection of patients for taxane chemotherapy. taxane 94-100 Ras association domain family member 1 Homo sapiens 9-15 22530128-3 2012 In this paper, DNA promoter methylation of five C-terminal Ras-association family members (RASSF1A, RASSF2A, RASSF4, RASSF5, and RASSF6) was studied in 64 formalin-fixed paraffin-embedded (FFPE) bladder cancer and normal adjacent tissues using methylation-specific high-resolution melting (MS-HRM) analysis. Formaldehyde 155-163 Ras association domain family member 1 Homo sapiens 91-98 22548172-4 2012 We have observed a strong correlation between the loss of RASSF1A expression and the development of Taxol resistance in primary ovarian cancer samples. Paclitaxel 100-105 Ras association domain family member 1 Homo sapiens 58-65 22530128-3 2012 In this paper, DNA promoter methylation of five C-terminal Ras-association family members (RASSF1A, RASSF2A, RASSF4, RASSF5, and RASSF6) was studied in 64 formalin-fixed paraffin-embedded (FFPE) bladder cancer and normal adjacent tissues using methylation-specific high-resolution melting (MS-HRM) analysis. Paraffin 170-178 Ras association domain family member 1 Homo sapiens 91-98 22548172-6 2012 We found that knocking down RASSF1A expression in an ovarian cancer cell line inhibited Taxol-mediated apoptosis and promoted cell survival during Taxol treatment. Paclitaxel 88-93 Ras association domain family member 1 Homo sapiens 28-35 22548172-6 2012 We found that knocking down RASSF1A expression in an ovarian cancer cell line inhibited Taxol-mediated apoptosis and promoted cell survival during Taxol treatment. Paclitaxel 147-152 Ras association domain family member 1 Homo sapiens 28-35 22139571-10 2011 Chromatin immunoprecipitation using antibodies against the acetylated and trimethylated lysine 9 of histone H3 demonstrated low levels of histone methylation in these genes, which are located closest to RASSF1. Lysine 88-94 Ras association domain family member 1 Homo sapiens 203-209 22548172-8 2012 This identifies a role for RASSF1A in modulating the tumor response to Taxol and provides proof of principal for the use of epigenetic therapy to overcome Taxol resistance. Paclitaxel 71-76 Ras association domain family member 1 Homo sapiens 27-34 23147544-0 2012 RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Docetaxel 166-175 Ras association domain family member 1 Homo sapiens 0-7 23147544-0 2012 RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Cisplatin 180-189 Ras association domain family member 1 Homo sapiens 0-7 23147544-1 2012 BACKGROUND: The purpose of this study was to test the hypothesis that the immunohistochemical expression of ERCC1 and RASSF1A would predict both response to and survival after docetaxel and cisplatin combination chemotherapy in inoperable or recurrent head and neck squamous cell carcinoma. Docetaxel 176-185 Ras association domain family member 1 Homo sapiens 118-125 23147544-1 2012 BACKGROUND: The purpose of this study was to test the hypothesis that the immunohistochemical expression of ERCC1 and RASSF1A would predict both response to and survival after docetaxel and cisplatin combination chemotherapy in inoperable or recurrent head and neck squamous cell carcinoma. Cisplatin 190-199 Ras association domain family member 1 Homo sapiens 118-125 23251702-7 2012 RESULTS: The TMCG/DIPY combination acted as an epigenetic treatment that reactivated RASSF1A expression and induced apoptosis in breast cancer cells. tmcg 13-17 Ras association domain family member 1 Homo sapiens 85-92 23251702-7 2012 RESULTS: The TMCG/DIPY combination acted as an epigenetic treatment that reactivated RASSF1A expression and induced apoptosis in breast cancer cells. Dipyridamole 18-22 Ras association domain family member 1 Homo sapiens 85-92 23251702-9 2012 The ChIP assay showed enhancement of E2F1 occupancy at the unmethylated RASSF1A promoter after TMCG/DIPY treatment. tmcg 95-99 Ras association domain family member 1 Homo sapiens 72-79 23251702-9 2012 The ChIP assay showed enhancement of E2F1 occupancy at the unmethylated RASSF1A promoter after TMCG/DIPY treatment. Dipyridamole 100-104 Ras association domain family member 1 Homo sapiens 72-79 23251702-10 2012 Interestingly, inhibition of E2F1 demethylation using an irreversible inhibitor of lysine-specific demethylase 1 reduced both TMCG/DIPY-mediated RASSF1A expression and apoptosis in MDA-MB-231 cells, suggesting that DNA and protein demethylation may act together to control these molecular and cellular processes. Lysine 83-89 Ras association domain family member 1 Homo sapiens 145-152 23251702-10 2012 Interestingly, inhibition of E2F1 demethylation using an irreversible inhibitor of lysine-specific demethylase 1 reduced both TMCG/DIPY-mediated RASSF1A expression and apoptosis in MDA-MB-231 cells, suggesting that DNA and protein demethylation may act together to control these molecular and cellular processes. tmcg 126-130 Ras association domain family member 1 Homo sapiens 145-152 23251702-10 2012 Interestingly, inhibition of E2F1 demethylation using an irreversible inhibitor of lysine-specific demethylase 1 reduced both TMCG/DIPY-mediated RASSF1A expression and apoptosis in MDA-MB-231 cells, suggesting that DNA and protein demethylation may act together to control these molecular and cellular processes. Dipyridamole 131-135 Ras association domain family member 1 Homo sapiens 145-152 21873787-1 2011 OBJECTIVE: To explore the relation between methylation status of RAS association domain family 1A (RASSF1A) in patients with advanced epithelial ovarian cancer and the clinical efficacy of cisplatin based neoadjuvant therapy. Cisplatin 189-198 Ras association domain family member 1 Homo sapiens 65-97 21221769-7 2011 Methylated RASSF1A in PB-P was also an indicator for poor OAS and DDFS (P = 0.001 and P = 0.004). pb-p 22-26 Ras association domain family member 1 Homo sapiens 11-18 21880625-4 2011 Treatment of UW228-3 cells stably expressing RASSF1A with an anti-CD95 antibody to induce extrinsic apoptosis and etoposide or cisplatin to activate intrinsic apoptosis augmented tumor cell killing in a caspase-dependent manner. Etoposide 114-123 Ras association domain family member 1 Homo sapiens 45-52 21880625-6 2011 On the basis of this knowledge, we demonstrate how the loss of RASSF1A function in medulloblastoma cells might be overcome using the novel BH3-only mimetic ABT-737 in combination with chemotherapeutic agents to target the BCL-2 anti-apoptotic members. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 156-159 Ras association domain family member 1 Homo sapiens 63-70 21873787-1 2011 OBJECTIVE: To explore the relation between methylation status of RAS association domain family 1A (RASSF1A) in patients with advanced epithelial ovarian cancer and the clinical efficacy of cisplatin based neoadjuvant therapy. Cisplatin 189-198 Ras association domain family member 1 Homo sapiens 99-106 20978370-9 2011 Overall, folate was associated with increased methylation levels of RASSF1A and MTHFR and methionine was associated with decreased methylation levels of RASSF1A. Folic Acid 9-15 Ras association domain family member 1 Homo sapiens 68-75 21473856-3 2011 However, the suppressive effect of RASSF1A on K-RasV12-induced ROS increase and DNA damage has not been identified. Reactive Oxygen Species 63-66 Ras association domain family member 1 Homo sapiens 35-42 21473856-4 2011 Here, we show that RASSF1A blocks K-RasV12-triggered ROS production. Reactive Oxygen Species 53-56 Ras association domain family member 1 Homo sapiens 19-26 21473856-6 2011 From the results obtained in this study, we suggest that RASSF1A regulates the cellular ROS levels enhanced by the Ras signaling pathway, and that it may function as a tumor suppressor by suppressing DNA damage caused by activated Ras. Reactive Oxygen Species 88-91 Ras association domain family member 1 Homo sapiens 57-64 20497257-7 2011 Chromatin immunoprecipitation and real-time polymerase chain reaction analyses revealed that treatment with 5-aza-dC restored RASSF1A expression through a loss of gene silencing H3-K9 methylation and by retention of gene activating H3-K4 tri-methylation in the promoter region. Azacitidine 108-113 Ras association domain family member 1 Homo sapiens 126-133 20497257-10 2011 Our results indicate that the effects of 5-aza-dC on histone methylation profiles are gene-specific and that aberrant histone modifications may serve as a principal means of misregulation of RASSF1A and POU5F1 expression in testis cancer. Decitabine 41-49 Ras association domain family member 1 Homo sapiens 191-198 21199877-3 2011 Data from dephosphorylation assays and reduced activation of MST1/2 seen after RASSF1A depletion suggest that dephosphorylation of MST1/2 on Thr-183 and Thr-180 by PP2A is prevented by RASSF1A, shifting the balance of MST1/2 to the activated autophosphorylated form. Threonine 141-144 Ras association domain family member 1 Homo sapiens 79-86 21199877-3 2011 Data from dephosphorylation assays and reduced activation of MST1/2 seen after RASSF1A depletion suggest that dephosphorylation of MST1/2 on Thr-183 and Thr-180 by PP2A is prevented by RASSF1A, shifting the balance of MST1/2 to the activated autophosphorylated form. Threonine 141-144 Ras association domain family member 1 Homo sapiens 185-192 21199877-3 2011 Data from dephosphorylation assays and reduced activation of MST1/2 seen after RASSF1A depletion suggest that dephosphorylation of MST1/2 on Thr-183 and Thr-180 by PP2A is prevented by RASSF1A, shifting the balance of MST1/2 to the activated autophosphorylated form. Threonine 153-156 Ras association domain family member 1 Homo sapiens 79-86 21199877-3 2011 Data from dephosphorylation assays and reduced activation of MST1/2 seen after RASSF1A depletion suggest that dephosphorylation of MST1/2 on Thr-183 and Thr-180 by PP2A is prevented by RASSF1A, shifting the balance of MST1/2 to the activated autophosphorylated form. Threonine 153-156 Ras association domain family member 1 Homo sapiens 185-192 20978370-9 2011 Overall, folate was associated with increased methylation levels of RASSF1A and MTHFR and methionine was associated with decreased methylation levels of RASSF1A. Folic Acid 9-15 Ras association domain family member 1 Homo sapiens 153-160 20978370-9 2011 Overall, folate was associated with increased methylation levels of RASSF1A and MTHFR and methionine was associated with decreased methylation levels of RASSF1A. Methionine 90-100 Ras association domain family member 1 Homo sapiens 153-160 20184324-4 2010 Recently, we designed and synthesized a fluorescent carbazole analogue of mahanine (alkaloid from Murraya koenigii) that restored RASSF1A mRNA expression. carbazole 52-61 Ras association domain family member 1 Homo sapiens 130-137 20563638-13 2010 Elevated RASSF1A and/or TWIST1 methylation was significantly associated with phyllodes tumours compared with fibroadenomas (P = 0.02), TWIST1 methylation correlated with increasing malignancy in phyllodes tumours (P < 0.001). phyllodes 77-86 Ras association domain family member 1 Homo sapiens 9-16 21062731-6 2010 5-Azacytidine reversed hypermethylation in the promoter of tumor suppressor gene RASSF1a in the H226 cells at a 6000-fold lower concentration than its IC50. Azacitidine 0-13 Ras association domain family member 1 Homo sapiens 81-88 20655196-0 2010 Protein kinase A-mediated phosphorylation of the RASSF1A tumour suppressor at Serine 203 and regulation of RASSF1A function. Serine 78-84 Ras association domain family member 1 Homo sapiens 49-56 20655196-4 2010 RASSF1A is mainly phosphorylated at Serine 203 within its Ras association domain. Serine 36-42 Ras association domain family member 1 Homo sapiens 0-7 20642860-4 2010 MATERIALS AND METHODS: Bisulfite pyrosequencing is used to screen 6 putative tumor suppressor genes (HIN-1, RASSF1A, RIL, CDH13, RARbeta2 and E-cadherin) in 38 pairs of primary breast tumors and lymph node metastases. hydrogen sulfite 23-32 Ras association domain family member 1 Homo sapiens 108-115 21473137-1 2011 OBJECTIVE: To investigate the effect of 5-Aza-dC and TSA to tumor suppressor gene RASSF1A expression and methylation level in Hep-2 cell line. Azacitidine 40-45 Ras association domain family member 1 Homo sapiens 82-89 21473137-1 2011 OBJECTIVE: To investigate the effect of 5-Aza-dC and TSA to tumor suppressor gene RASSF1A expression and methylation level in Hep-2 cell line. trichostatin A 53-56 Ras association domain family member 1 Homo sapiens 82-89 21473137-5 2011 (2) With the effect of 5-Aza-dC and TSA, the methylation of RASSF1A gene was reversed. Decitabine 23-31 Ras association domain family member 1 Homo sapiens 60-67 21473137-5 2011 (2) With the effect of 5-Aza-dC and TSA, the methylation of RASSF1A gene was reversed. trichostatin A 36-39 Ras association domain family member 1 Homo sapiens 60-67 21473137-8 2011 (3) With the effect of 5-Aza-dC and TSA, the expression of RASSF1A was improved. Decitabine 23-31 Ras association domain family member 1 Homo sapiens 59-66 21473137-8 2011 (3) With the effect of 5-Aza-dC and TSA, the expression of RASSF1A was improved. trichostatin A 36-39 Ras association domain family member 1 Homo sapiens 59-66 21473137-12 2011 5-Aza-dC and TSA can improve RASSF1A expression by reversing DNA methylation and histone deacetylation. Decitabine 0-8 Ras association domain family member 1 Homo sapiens 29-36 21473137-12 2011 5-Aza-dC and TSA can improve RASSF1A expression by reversing DNA methylation and histone deacetylation. trichostatin A 13-16 Ras association domain family member 1 Homo sapiens 29-36 20038516-5 2010 The methylation level of 5" CpG islands in the RASSF1A was evaluated using combined bisulfite restriction analysis and bisulfite sequencing. hydrogen sulfite 84-93 Ras association domain family member 1 Homo sapiens 47-54 20038516-5 2010 The methylation level of 5" CpG islands in the RASSF1A was evaluated using combined bisulfite restriction analysis and bisulfite sequencing. hydrogen sulfite 119-128 Ras association domain family member 1 Homo sapiens 47-54 20490964-7 2010 There was a significant association between CIMP and methylation of RASSF1A, BRCA1, p16, CDH1, ER, RARbeta2, APC, and DAPK (P < 0.05); the methylation link profile of CDH1, RASSF1A, BRCA1, and RARbeta2 as breast cancer marker may contribute high sensitivity (90%) and specificity (88%). Cyclic IMP 44-48 Ras association domain family member 1 Homo sapiens 68-75 20490964-7 2010 There was a significant association between CIMP and methylation of RASSF1A, BRCA1, p16, CDH1, ER, RARbeta2, APC, and DAPK (P < 0.05); the methylation link profile of CDH1, RASSF1A, BRCA1, and RARbeta2 as breast cancer marker may contribute high sensitivity (90%) and specificity (88%). Cyclic IMP 44-48 Ras association domain family member 1 Homo sapiens 176-183 20184324-4 2010 Recently, we designed and synthesized a fluorescent carbazole analogue of mahanine (alkaloid from Murraya koenigii) that restored RASSF1A mRNA expression. mahanine 74-82 Ras association domain family member 1 Homo sapiens 130-137 20069457-8 2010 Mutation of these critical serines resulted in the loss of 14-3-3 association and earlier recruitment of RASSF1A to MOAP-1, TNF-R1, and TRAIL-R1. Serine 27-34 Ras association domain family member 1 Homo sapiens 105-112 20069457-9 2010 Furthermore, stable cells containing a triple serine mutant of RASSF1A [serine (S) 175 to alanine (A) [S175A], S178A, and S179A] resulted in increased basal cell death, enhanced Annexin V staining and enhanced cleavage of poly (ADP-ribose) polymerase (PARP) following TNFalpha stimulation when compared to stable cells containing wild type RASSF1A. Serine 46-52 Ras association domain family member 1 Homo sapiens 63-70 20069457-9 2010 Furthermore, stable cells containing a triple serine mutant of RASSF1A [serine (S) 175 to alanine (A) [S175A], S178A, and S179A] resulted in increased basal cell death, enhanced Annexin V staining and enhanced cleavage of poly (ADP-ribose) polymerase (PARP) following TNFalpha stimulation when compared to stable cells containing wild type RASSF1A. Serine 46-52 Ras association domain family member 1 Homo sapiens 340-347 20069457-9 2010 Furthermore, stable cells containing a triple serine mutant of RASSF1A [serine (S) 175 to alanine (A) [S175A], S178A, and S179A] resulted in increased basal cell death, enhanced Annexin V staining and enhanced cleavage of poly (ADP-ribose) polymerase (PARP) following TNFalpha stimulation when compared to stable cells containing wild type RASSF1A. Serine 72-78 Ras association domain family member 1 Homo sapiens 63-70 20069457-9 2010 Furthermore, stable cells containing a triple serine mutant of RASSF1A [serine (S) 175 to alanine (A) [S175A], S178A, and S179A] resulted in increased basal cell death, enhanced Annexin V staining and enhanced cleavage of poly (ADP-ribose) polymerase (PARP) following TNFalpha stimulation when compared to stable cells containing wild type RASSF1A. Serine 72-78 Ras association domain family member 1 Homo sapiens 340-347 20069457-9 2010 Furthermore, stable cells containing a triple serine mutant of RASSF1A [serine (S) 175 to alanine (A) [S175A], S178A, and S179A] resulted in increased basal cell death, enhanced Annexin V staining and enhanced cleavage of poly (ADP-ribose) polymerase (PARP) following TNFalpha stimulation when compared to stable cells containing wild type RASSF1A. Alanine 90-97 Ras association domain family member 1 Homo sapiens 63-70 20069457-9 2010 Furthermore, stable cells containing a triple serine mutant of RASSF1A [serine (S) 175 to alanine (A) [S175A], S178A, and S179A] resulted in increased basal cell death, enhanced Annexin V staining and enhanced cleavage of poly (ADP-ribose) polymerase (PARP) following TNFalpha stimulation when compared to stable cells containing wild type RASSF1A. Alanine 90-97 Ras association domain family member 1 Homo sapiens 340-347 19821102-1 2009 The relationship between Ala/Ser polymorphism in 133 codon of exon 3 region of the RASSF1 gene and genetic susceptibility of lung cancer in Hubei province Han population was investigated by a case-control study. Alanine 25-28 Ras association domain family member 1 Homo sapiens 83-89 20042089-7 2009 5-aza-dC was then added to confirm the correlation between hypermethylation status and inactivation of RASSF1A. Decitabine 0-8 Ras association domain family member 1 Homo sapiens 103-110 20042089-10 2009 Meanwhile, trypan blue dye exclusion assays was used to detect the effect of RASSF1A transfection alone and the co-transfection of RASSF1A and K-Ras on cell proliferation. Trypan Blue 11-22 Ras association domain family member 1 Homo sapiens 77-84 20042089-14 2009 Loss of RASSF1A expression was greatly restored by the methyltransferase inhibitor 5-aza-dC in CNE-2. Decitabine 83-91 Ras association domain family member 1 Homo sapiens 8-15 19637319-12 2009 Treatment with 5-aza-2"-deoxycytidine resulted in the re-expression of the unmethylated form of RASSF1A in two ES cell lines. Decitabine 15-37 Ras association domain family member 1 Homo sapiens 96-103 19695681-4 2009 In this study, we determined the methylation frequency of 5 genes, including p16, Runx3, MGMT, DAPK, and RASSF1A, by methylation-specific polymerase chain reaction, in a series of formalin-fixed paraffin-embedded tissues including normal gastric mucosa (n = 20), intestinal metaplasia (n = 14), gastric epithelial dysplasia (n = 27), and early gastric adenocarcinoma (n = 16). Formaldehyde 180-188 Ras association domain family member 1 Homo sapiens 105-112 19695681-4 2009 In this study, we determined the methylation frequency of 5 genes, including p16, Runx3, MGMT, DAPK, and RASSF1A, by methylation-specific polymerase chain reaction, in a series of formalin-fixed paraffin-embedded tissues including normal gastric mucosa (n = 20), intestinal metaplasia (n = 14), gastric epithelial dysplasia (n = 27), and early gastric adenocarcinoma (n = 16). Paraffin 195-203 Ras association domain family member 1 Homo sapiens 105-112 19578875-5 2010 De-methylation of the cells by treatment with 5-Aza-dC induced re-expression of RASSF1A and growth suppression of the cells. Decitabine 46-54 Ras association domain family member 1 Homo sapiens 80-87 19548140-1 2009 The aim was to determine whether promoter methylation of BRCA1, MGMT, MLH1, RASSF1A, and p16 genes could predict response to platinum-based chemotherapy. Platinum 125-133 Ras association domain family member 1 Homo sapiens 76-83 19821102-1 2009 The relationship between Ala/Ser polymorphism in 133 codon of exon 3 region of the RASSF1 gene and genetic susceptibility of lung cancer in Hubei province Han population was investigated by a case-control study. Serine 29-32 Ras association domain family member 1 Homo sapiens 83-89 19276349-3 2009 Here, we show that Aurora A and B associate with and phosphorylate RASSF1A on serine 203 in vivo at different times and in different subcellular compartments during mitosis. Serine 78-84 Ras association domain family member 1 Homo sapiens 67-74 19763613-5 2009 The methylation level of examined genes was significantly higher in BilIN than in normal samples (TMEFF2, HOXA1, NEUROG1, and RUNX3, P < 0.05) and in EHC than in BilIN samples (TMEFF2, HOXA1, NEUROG1, RUNX3, RASSF1A, and APC, P < 0.05). Bile Pigments 68-73 Ras association domain family member 1 Homo sapiens 211-218 19374895-3 2009 The prognostic significance of RASSF1A methylation was validated in 93 formalin fixed paraffin-embedded (FFPE) tissues obtained from patients with operable breast cancer. Formaldehyde 71-79 Ras association domain family member 1 Homo sapiens 31-38 19374895-3 2009 The prognostic significance of RASSF1A methylation was validated in 93 formalin fixed paraffin-embedded (FFPE) tissues obtained from patients with operable breast cancer. Paraffin 86-94 Ras association domain family member 1 Homo sapiens 31-38 19957692-6 2009 RESULTS: The percentage of RASSF1A hypermethylation in RB tissues (60.7%) was statistically higher than in normal retinal tissue 0% (0/5) and adjacent non-neoplastic retinal tissue 17.9% (5/28) (P < 0.01), the hypermethylation percentage in unilateral RB group was higher than bilateral RB group either. Rubidium 55-57 Ras association domain family member 1 Homo sapiens 27-34 19567146-0 2009 RASSF1A expression inhibits cell growth and enhances cell chemosensitivity to mitomycin in BEL-7402 hepatocellular carcinoma cells. Mitomycin 78-87 Ras association domain family member 1 Homo sapiens 0-7 19567146-7 2009 Re-expression of wild-type RASSF1A could enhance the inhibition of cell proliferation and the percentage of apoptotic cells following cell treatment with mitomycin, but had no significant effect when combined with adriamycin, etoposide, 5-fluorouracil and cisplatin treatment. Mitomycin 154-163 Ras association domain family member 1 Homo sapiens 27-34 19567146-7 2009 Re-expression of wild-type RASSF1A could enhance the inhibition of cell proliferation and the percentage of apoptotic cells following cell treatment with mitomycin, but had no significant effect when combined with adriamycin, etoposide, 5-fluorouracil and cisplatin treatment. Doxorubicin 214-224 Ras association domain family member 1 Homo sapiens 27-34 19567146-7 2009 Re-expression of wild-type RASSF1A could enhance the inhibition of cell proliferation and the percentage of apoptotic cells following cell treatment with mitomycin, but had no significant effect when combined with adriamycin, etoposide, 5-fluorouracil and cisplatin treatment. Fluorouracil 237-251 Ras association domain family member 1 Homo sapiens 27-34 19567146-7 2009 Re-expression of wild-type RASSF1A could enhance the inhibition of cell proliferation and the percentage of apoptotic cells following cell treatment with mitomycin, but had no significant effect when combined with adriamycin, etoposide, 5-fluorouracil and cisplatin treatment. Cisplatin 256-265 Ras association domain family member 1 Homo sapiens 27-34 19567146-8 2009 CONCLUSION: Wild-type RASSF1A inhibits cell growth and enhances cell chemosensitivity to mitomycin in hepatocellular carcinoma, suggesting that RASSF1A may serve as a new target for gene therapy in hepatocellular carcinoma patients. Mitomycin 89-98 Ras association domain family member 1 Homo sapiens 22-29 19567146-8 2009 CONCLUSION: Wild-type RASSF1A inhibits cell growth and enhances cell chemosensitivity to mitomycin in hepatocellular carcinoma, suggesting that RASSF1A may serve as a new target for gene therapy in hepatocellular carcinoma patients. Mitomycin 89-98 Ras association domain family member 1 Homo sapiens 144-151 20079060-1 2009 OBJECTIVE: To investigate the effect of arsenic trioxide (As2O3) on expression of anti-oncogene RAS association domain family gene 1A(RASSF1A) in nasopharyngeal carcinoma cell line CNE-2Z. Arsenic Trioxide 40-56 Ras association domain family member 1 Homo sapiens 134-141 20079060-1 2009 OBJECTIVE: To investigate the effect of arsenic trioxide (As2O3) on expression of anti-oncogene RAS association domain family gene 1A(RASSF1A) in nasopharyngeal carcinoma cell line CNE-2Z. Arsenic Trioxide 58-63 Ras association domain family member 1 Homo sapiens 134-141 20079060-11 2009 After the effect of As2O3, the methylation of RASSF1A gene became weaker by increasing the concentration of As2O3; and the expression of RASSF1A gene became stronger at mRNA and protein level. Arsenic Trioxide 20-25 Ras association domain family member 1 Homo sapiens 46-53 20079060-11 2009 After the effect of As2O3, the methylation of RASSF1A gene became weaker by increasing the concentration of As2O3; and the expression of RASSF1A gene became stronger at mRNA and protein level. Arsenic Trioxide 20-25 Ras association domain family member 1 Homo sapiens 137-144 20079060-11 2009 After the effect of As2O3, the methylation of RASSF1A gene became weaker by increasing the concentration of As2O3; and the expression of RASSF1A gene became stronger at mRNA and protein level. Arsenic Trioxide 108-113 Ras association domain family member 1 Homo sapiens 46-53 20079060-13 2009 Along with increasing the concentration of As2O3, the expression of RASSF1A gene became stronger at mRNA and protein level, the methylation of RASSF1A gene became weaker and weaker. Arsenic Trioxide 43-48 Ras association domain family member 1 Homo sapiens 68-75 20079060-13 2009 Along with increasing the concentration of As2O3, the expression of RASSF1A gene became stronger at mRNA and protein level, the methylation of RASSF1A gene became weaker and weaker. Arsenic Trioxide 43-48 Ras association domain family member 1 Homo sapiens 143-150 20079060-14 2009 CONCLUSIONS: As2O3 can activate the expression of RASSF1A gene to inhibit the cell cycle progress of nasopharyngeal carcinoma cell line. Arsenic Trioxide 13-18 Ras association domain family member 1 Homo sapiens 50-57 19091744-1 2009 The Rassf1-6 polypeptides each contain a Ras/Rap association domain, which enables binding to several GTP-charged Ras-like GTPases, at least in vitro or when overexpressed. Guanosine Triphosphate 102-105 Ras association domain family member 1 Homo sapiens 4-12 19276349-7 2009 Finally, RASSF1A phosphorylation on serine 203 was up-regulated in Aurora A-overexpressing human tumors. Serine 36-42 Ras association domain family member 1 Homo sapiens 9-16 19145506-1 2009 OBJECTIVE: To investigate the effect of demethylating agent 5-Aza-CdR (5-aza-2"- deoxycytidine) on demethylation and transcription-regulating of RASSF1A gene in gastric cancer cell SGC7901 in vitro, as well as on the growth inhibition of cells. Decitabine 71-94 Ras association domain family member 1 Homo sapiens 145-152 17683489-10 2008 In addition, the wt-RASSF1A expression increased cell growth inhibition and the percentage of cells with sub-G(1) DNA content when the cells were treated with mitomycin. Mitomycin 159-168 Ras association domain family member 1 Homo sapiens 20-27 19002696-1 2008 PURPOSE: The aim of the current study was to investigate effects of CO(2) atmosphere, mimicking conditions of the pneumoperitoneum during laparoscopy, on epigenetic conditions of Rassf1A and DCR2 oncogenes in neuroblastoma cells. Carbon Dioxide 68-73 Ras association domain family member 1 Homo sapiens 179-186 18821524-5 2008 Network analysis demonstrated importance of a Plag1/CNK1/RASSF1A/Src-dependent prozone effect, as a systemic feature which is crucial for TGFbeta1-dependent activation of Erk1/2 and regulation of cell proliferation. prozone 79-86 Ras association domain family member 1 Homo sapiens 57-64 19024105-9 2008 RASSF1A promoter methylation from cells treated by siRNA-deltaDNMT3B4/2 was detected using MSP and Bisulfite sequencing, and Western blotting was used to detect the protein expression of DNMT3B and ADNMT3B. hydrogen sulfite 99-108 Ras association domain family member 1 Homo sapiens 0-7 18799029-1 2008 BACKGROUND & OBJECTIVE: The potential molecular mechanisms of the antitumor role of Ras association domain family 1 A (RASSF1A) has not been well understood. Adenosine Monophosphate 12-15 Ras association domain family member 1 Homo sapiens 88-121 18799029-1 2008 BACKGROUND & OBJECTIVE: The potential molecular mechanisms of the antitumor role of Ras association domain family 1 A (RASSF1A) has not been well understood. Adenosine Monophosphate 12-15 Ras association domain family member 1 Homo sapiens 123-130 18474619-6 2008 RASSF1A associated with the TNF-R1/MOAP-1 or TRAIL-R1/MOAP-1 complex via its N-terminal cysteine-rich (C1) domain containing a potential zinc finger binding motif. Cysteine 88-96 Ras association domain family member 1 Homo sapiens 0-7 18404674-7 2008 mRNA expression of RASSF1A, RASSF2A and BLU in endometrial cancer cell lines significantly increased after treatment with the demethylating agent 5-Aza-2"-deoxycytidine supporting the repressive effect of hypermethylation on their transcription. Decitabine 146-168 Ras association domain family member 1 Homo sapiens 19-26 18071316-4 2008 This Skp2-dependent destruction of RASSF1A requires phosphorylation of the latter on serine-203 by cyclin D-cyclin-dependent kinase 4. Serine 85-91 Ras association domain family member 1 Homo sapiens 35-42 18514071-1 2008 Ras association domain family 1A (RASSF1A) is a tumour suppressor that contains an amino-terminal cysteine-rich region, similar to the diacylglycerol (DAG)-binding domain (C1 domain) found in the protein kinase C (PKC) family of proteins, and a carboxy-terminal Ras-association (RA) domain. Cysteine 98-106 Ras association domain family member 1 Homo sapiens 0-32 18514071-1 2008 Ras association domain family 1A (RASSF1A) is a tumour suppressor that contains an amino-terminal cysteine-rich region, similar to the diacylglycerol (DAG)-binding domain (C1 domain) found in the protein kinase C (PKC) family of proteins, and a carboxy-terminal Ras-association (RA) domain. Cysteine 98-106 Ras association domain family member 1 Homo sapiens 34-41 18514071-1 2008 Ras association domain family 1A (RASSF1A) is a tumour suppressor that contains an amino-terminal cysteine-rich region, similar to the diacylglycerol (DAG)-binding domain (C1 domain) found in the protein kinase C (PKC) family of proteins, and a carboxy-terminal Ras-association (RA) domain. Diglycerides 135-149 Ras association domain family member 1 Homo sapiens 0-32 18514071-1 2008 Ras association domain family 1A (RASSF1A) is a tumour suppressor that contains an amino-terminal cysteine-rich region, similar to the diacylglycerol (DAG)-binding domain (C1 domain) found in the protein kinase C (PKC) family of proteins, and a carboxy-terminal Ras-association (RA) domain. Diglycerides 135-149 Ras association domain family member 1 Homo sapiens 34-41 18514071-1 2008 Ras association domain family 1A (RASSF1A) is a tumour suppressor that contains an amino-terminal cysteine-rich region, similar to the diacylglycerol (DAG)-binding domain (C1 domain) found in the protein kinase C (PKC) family of proteins, and a carboxy-terminal Ras-association (RA) domain. Diglycerides 151-154 Ras association domain family member 1 Homo sapiens 0-32 18514071-1 2008 Ras association domain family 1A (RASSF1A) is a tumour suppressor that contains an amino-terminal cysteine-rich region, similar to the diacylglycerol (DAG)-binding domain (C1 domain) found in the protein kinase C (PKC) family of proteins, and a carboxy-terminal Ras-association (RA) domain. Diglycerides 151-154 Ras association domain family member 1 Homo sapiens 34-41 18322962-2 2008 METHODS: Through over-expression of RASSF1A gene in the SGC7901 cell line which was induced by a lipofectamine-mediated gene transfer approach. Lipofectamine 97-110 Ras association domain family member 1 Homo sapiens 36-43 18330258-7 2007 The expression of RASSF1A mRNA was up-regulated in CNE-2Z cells treated with procaine, but no obvious change was found in the expression of p16 mRNA. Procaine 77-85 Ras association domain family member 1 Homo sapiens 18-25 17563743-8 2007 Substitutions of these residues with glutamic acid at both positions, mimicking constitutive phosphorylation of RASSF1A, disrupt RASSF1A interactions with microtubules and abolish its ability to induce M-phase cell cycle arrest. Glutamic Acid 37-50 Ras association domain family member 1 Homo sapiens 112-119 17563743-8 2007 Substitutions of these residues with glutamic acid at both positions, mimicking constitutive phosphorylation of RASSF1A, disrupt RASSF1A interactions with microtubules and abolish its ability to induce M-phase cell cycle arrest. Glutamic Acid 37-50 Ras association domain family member 1 Homo sapiens 129-136 18203293-0 2008 Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB. nab 130-133 Ras association domain family member 1 Homo sapiens 49-56 18203293-6 2008 The combined treatment of 5-Aza-CdR and NaB induced complete demethylation of RASSF1A gene, leading to a significantly higher re-expression of the mRNA and protein of RASSF1A than those treated with 5-Aza-CdR alone (P<0.05). nab 40-43 Ras association domain family member 1 Homo sapiens 78-85 18203293-6 2008 The combined treatment of 5-Aza-CdR and NaB induced complete demethylation of RASSF1A gene, leading to a significantly higher re-expression of the mRNA and protein of RASSF1A than those treated with 5-Aza-CdR alone (P<0.05). nab 40-43 Ras association domain family member 1 Homo sapiens 167-174 19098985-5 2008 Likewise, RASSF1A tumor suppressor was proteolyzed by the H358 cell extract. ZINC78587988 58-62 Ras association domain family member 1 Homo sapiens 10-17 17563743-7 2007 Aurora-A appears to phosphorylate RASSF1A at Threonine202 and/or Serine203 that reside within the known microtubule-binding domain of RASSF1A. threonine202 45-57 Ras association domain family member 1 Homo sapiens 34-41 17563743-7 2007 Aurora-A appears to phosphorylate RASSF1A at Threonine202 and/or Serine203 that reside within the known microtubule-binding domain of RASSF1A. serine203 65-74 Ras association domain family member 1 Homo sapiens 134-141 18330258-8 2007 CONCLUSION: Procaine could inhibit cell growth and up-regulate the expression of RASSF1A mRNA, which may play an important role in CNE-2Z cells" proliferation inhibition induced by procaine. Procaine 12-20 Ras association domain family member 1 Homo sapiens 81-88 18330258-8 2007 CONCLUSION: Procaine could inhibit cell growth and up-regulate the expression of RASSF1A mRNA, which may play an important role in CNE-2Z cells" proliferation inhibition induced by procaine. Procaine 181-189 Ras association domain family member 1 Homo sapiens 81-88 17698033-0 2007 Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. mahanine 0-8 Ras association domain family member 1 Homo sapiens 67-74 17698033-4 2007 Mahanine-induced expression of RASSF1A in turn significantly reduced cyclin D1 but not other cyclins. mahanine 0-8 Ras association domain family member 1 Homo sapiens 31-38 17698033-5 2007 To understand the inverse relationship between RASSF1A and cyclin D1, we observed that mahanine treatment down-regulates cyclin D1 and addition of RASSF1A siRNA prevented this inhibition. mahanine 87-95 Ras association domain family member 1 Homo sapiens 47-54 17938735-9 2007 RASSF1A and p16 promoter regions were heavily methylated in CTPE cells, indicating silencing by hypermethylation, while the DNA demethylating agent, 5-aza-2"-deoxycytidine, reversed this silencing. ctpe 60-64 Ras association domain family member 1 Homo sapiens 0-7 17689283-4 2007 RASSF1A, commonly methylated at high frequency in many tumors including melanoma, which we discovered to be also an IFN-regulated gene, was increased by 5-Aza-dC. Decitabine 153-161 Ras association domain family member 1 Homo sapiens 0-7 17689283-5 2007 RASSF1A was important in enhancing apoptotic effects of not only IFNs and APO2L/TRAIL but also cisplatin. Cisplatin 95-104 Ras association domain family member 1 Homo sapiens 0-7 17641842-2 2007 In order to further explore the epigenetic mechanism of tumor suppressor gene RASSF1A inactivation, 5-aza-2"-deoxycytidine (5-Aza-CdR), a DNA methyltransferase inhibitor, was used to treat the human biliary tract carcinoma cell line QBC-939 at the concentration of 5 micromol/L for 24 h in this study. Decitabine 100-122 Ras association domain family member 1 Homo sapiens 78-85 17473182-8 2007 The ChIP assays showed enhancement of histone acetylation and dimethyl-H3-K4 methylation on the unmethylated RASSF1A promoter. dimethyl-h3-k4 62-76 Ras association domain family member 1 Homo sapiens 109-116 17444856-3 2007 METHODS: Methylation status of RASSF1A from genomic gene of SMMC-7721 was determined with methylation-specific polymerase chain reaction and was further verified by demethylation treatment with 5-aza-2"-deoxycytidine. Decitabine 194-216 Ras association domain family member 1 Homo sapiens 31-38 17444856-4 2007 Wild-type RASSF1A cDNA was introduced into SMMC-7721; chemosensitivity to cisplatin, mitomycin and fluorouracil were analyzed using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide assay. smmc 43-47 Ras association domain family member 1 Homo sapiens 10-17 17444856-4 2007 Wild-type RASSF1A cDNA was introduced into SMMC-7721; chemosensitivity to cisplatin, mitomycin and fluorouracil were analyzed using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide assay. Mitomycin 85-94 Ras association domain family member 1 Homo sapiens 10-17 17444856-4 2007 Wild-type RASSF1A cDNA was introduced into SMMC-7721; chemosensitivity to cisplatin, mitomycin and fluorouracil were analyzed using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide assay. Cisplatin 74-83 Ras association domain family member 1 Homo sapiens 10-17 17444856-4 2007 Wild-type RASSF1A cDNA was introduced into SMMC-7721; chemosensitivity to cisplatin, mitomycin and fluorouracil were analyzed using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide assay. Fluorouracil 99-111 Ras association domain family member 1 Homo sapiens 10-17 17121881-3 2006 EXPERIMENTAL DESIGN: First, methylation status of a 4-kb region of RASSF1A promoter was interrogated using oligonucleotide-based microarray in 144 samples (primary tumors, 47; adjacent normals, 69; reduction mammoplasty tissues, 28). Oligonucleotides 107-122 Ras association domain family member 1 Homo sapiens 67-74 17444856-4 2007 Wild-type RASSF1A cDNA was introduced into SMMC-7721; chemosensitivity to cisplatin, mitomycin and fluorouracil were analyzed using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide assay. thiazolyl blue 132-194 Ras association domain family member 1 Homo sapiens 10-17 17196704-0 2007 Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. gemcitabine 120-131 Ras association domain family member 1 Homo sapiens 27-34 17322379-5 2007 An inverse relationship between RASSF1A promoter methylation and gene expression was demonstrated by bisulfite sequencing of microdissected placental cells and immunohistochemical staining of placental tissue sections using an anti-RASSF1A antibody. hydrogen sulfite 101-110 Ras association domain family member 1 Homo sapiens 32-39 17322379-6 2007 Treatment of choriocarcinoma cell lines, JAR and JEG3, by 5-aza-2"-deoxycytidine and trichostatin A led to reduction in RASSF1A methylation but increased expression. Decitabine 58-80 Ras association domain family member 1 Homo sapiens 120-127 17322379-6 2007 Treatment of choriocarcinoma cell lines, JAR and JEG3, by 5-aza-2"-deoxycytidine and trichostatin A led to reduction in RASSF1A methylation but increased expression. trichostatin A 85-99 Ras association domain family member 1 Homo sapiens 120-127 17088994-6 2006 These results demonstrate that RASSF1A inhibited H-RasG12V-induced JNK activation and JNK-mediated p27Kip1 down-regulation. h-rasg12v 49-58 Ras association domain family member 1 Homo sapiens 31-38 17526942-9 2006 The NCI-H727 and HTB-119 cells lines were methylated in the RASSF1A promoter region, and after treatment with 5-aza-2"-deoxycytidine (5-AZA), RASSF1A mRNA was expressed in both cell lines. Decitabine 110-132 Ras association domain family member 1 Homo sapiens 60-67 17526942-9 2006 The NCI-H727 and HTB-119 cells lines were methylated in the RASSF1A promoter region, and after treatment with 5-aza-2"-deoxycytidine (5-AZA), RASSF1A mRNA was expressed in both cell lines. Decitabine 110-132 Ras association domain family member 1 Homo sapiens 142-149 17088994-3 2006 Exogenous expression of H-RasG12V induced JNK phosphorylation and RASSF1A co-transfected with H-RasG12V efficiently suppressed Ras-triggered JNK activation in various cancer cell lines. h-rasg12v 24-33 Ras association domain family member 1 Homo sapiens 66-73 17088994-3 2006 Exogenous expression of H-RasG12V induced JNK phosphorylation and RASSF1A co-transfected with H-RasG12V efficiently suppressed Ras-triggered JNK activation in various cancer cell lines. h-rasg12v 94-103 Ras association domain family member 1 Homo sapiens 66-73 17088994-4 2006 RASSF1A expression revived the H-RasG12V-induced p27Kip1 down-regulation. h-rasg12v 31-40 Ras association domain family member 1 Homo sapiens 0-7 16186793-6 2006 Treatment of cell lines using 5-Aza-2"-deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma. Decitabine 30-52 Ras association domain family member 1 Homo sapiens 153-160 16331610-8 2006 In addition, RASSF1A hypermethylation was significantly more frequent in EAs than in CAs (81.0% vs. 33.3%, p = 0.001). CHEMBL4167713 73-76 Ras association domain family member 1 Homo sapiens 13-20 16331610-8 2006 In addition, RASSF1A hypermethylation was significantly more frequent in EAs than in CAs (81.0% vs. 33.3%, p = 0.001). Calcium 85-88 Ras association domain family member 1 Homo sapiens 13-20 17119258-7 2006 Arsenic exposure, measured as toenail arsenic, was associated with RASSF1A (P < 0.02) and PRSS3 (P < 0.1) but not p16(INK4A) or SFRP promotor methylation, in models adjusted for stage and other risk factors. Arsenic 0-7 Ras association domain family member 1 Homo sapiens 67-74 17119258-7 2006 Arsenic exposure, measured as toenail arsenic, was associated with RASSF1A (P < 0.02) and PRSS3 (P < 0.1) but not p16(INK4A) or SFRP promotor methylation, in models adjusted for stage and other risk factors. Arsenic 38-45 Ras association domain family member 1 Homo sapiens 67-74 16720314-9 2006 Moreover, the DNA methylation levels of the estrogen receptor (Er-beta), P16INK4a and RASSF1A were strongly decreased (from 35 to 70%) in the quercetin-treated group compared to the control. Quercetin 142-151 Ras association domain family member 1 Homo sapiens 86-93 16125301-2 2006 An association between a single nucleotide polymorphism (SNP) at codon 133 of the RASSF1 gene, encoding either alanine (GCT) or serine (TCT), and human cancer risk remains undefined. Alanine 111-118 Ras association domain family member 1 Homo sapiens 82-88 16125301-2 2006 An association between a single nucleotide polymorphism (SNP) at codon 133 of the RASSF1 gene, encoding either alanine (GCT) or serine (TCT), and human cancer risk remains undefined. 4,5-DIHYDROXY-TETRAHYDRO-PYRAN-2-CARBOXYLIC ACID 120-123 Ras association domain family member 1 Homo sapiens 82-88 16125301-2 2006 An association between a single nucleotide polymorphism (SNP) at codon 133 of the RASSF1 gene, encoding either alanine (GCT) or serine (TCT), and human cancer risk remains undefined. Serine 128-134 Ras association domain family member 1 Homo sapiens 82-88 16510573-6 2006 Moreover, the stimulatory effect of RASSF1A overexpression on Fas-induced apoptosis was inhibited by depletion of Mst1. ammonium ferrous sulfate 62-65 Ras association domain family member 1 Homo sapiens 36-43 16465383-7 2006 Treatment of cell lines with 5-aza-2"-deoxycytidine activated RASSF1A mRNA expression along with promoter demethylation. Decitabine 29-51 Ras association domain family member 1 Homo sapiens 62-69 16186793-6 2006 Treatment of cell lines using 5-Aza-2"-deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma. Decitabine 54-58 Ras association domain family member 1 Homo sapiens 153-160 16186793-6 2006 Treatment of cell lines using 5-Aza-2"-deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma. trichostatin A 89-103 Ras association domain family member 1 Homo sapiens 153-160 16186793-6 2006 Treatment of cell lines using 5-Aza-2"-deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma. trichostatin A 105-108 Ras association domain family member 1 Homo sapiens 153-160 15930345-5 2005 Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis. sybr green 16-26 Ras association domain family member 1 Homo sapiens 130-137 15987713-7 2006 Arsenic exposure, measured as toenail arsenic, was associated with RASSF1A (P<0.02) and PRSS3 (P<0.1) but not p16INK4A promoter methylation, in models adjusted for stage and other factors. Arsenic 0-7 Ras association domain family member 1 Homo sapiens 67-74 15987713-7 2006 Arsenic exposure, measured as toenail arsenic, was associated with RASSF1A (P<0.02) and PRSS3 (P<0.1) but not p16INK4A promoter methylation, in models adjusted for stage and other factors. Arsenic 38-45 Ras association domain family member 1 Homo sapiens 67-74 16757333-6 2006 By contrast, RASSF1, despite an RA domain 50% identical to Nore1, exhibits relatively low affinity for Ras-like GTPases but may associate with Ras-GTP indirectly. ras-gtp 143-150 Ras association domain family member 1 Homo sapiens 13-19 16012945-3 2005 METHODS: The expression and methylation status of 6 RASSF family genes were examined using RT-PCR and bisulfite PCR in CRC cell lines and in primary CRCs and colorectal adenomas. hydrogen sulfite 102-111 Ras association domain family member 1 Homo sapiens 52-57 15734995-4 2005 RASSF1A methylation 1 year after primary surgery (and during adjuvant tamoxifen therapy) was an independent predictor of poor outcome, with a relative risk (95% confidence interval) for relapse of 5.1 (1.3-19.8) and for death of 6.9 (1.9-25.9). Tamoxifen 70-79 Ras association domain family member 1 Homo sapiens 0-7 15799820-6 2005 There was no expression of RASSF1A transcripts in all hypermethylated samples, but RASSF1A transcripts were restored after 5-aza-2"-deoxycytidine treatment with no changes in cell cycle or apoptosis. Decitabine 123-145 Ras association domain family member 1 Homo sapiens 83-90 15911247-7 2005 Interestingly, inactivation of RASSF1A and p16 correlated well with an extended smoking habit (P=0.02), and exposure to asbestos (P=0.017) or squamous cell carcinoma (P=0.011), respectively. Asbestos 120-128 Ras association domain family member 1 Homo sapiens 31-38 15734995-5 2005 Measurement of serum DNA methylation allows adjuvant systemic treatment to be monitored for efficacy: disappearance of RASSF1A DNA methylation in serum throughout treatment with tamoxifen indicates a response, whereas persistence or new appearance means resistance to adjuvant tamoxifen treatment. Tamoxifen 178-187 Ras association domain family member 1 Homo sapiens 119-126 15734995-5 2005 Measurement of serum DNA methylation allows adjuvant systemic treatment to be monitored for efficacy: disappearance of RASSF1A DNA methylation in serum throughout treatment with tamoxifen indicates a response, whereas persistence or new appearance means resistance to adjuvant tamoxifen treatment. Tamoxifen 277-286 Ras association domain family member 1 Homo sapiens 119-126 15149548-9 2004 CONCLUSIONS: Our findings suggest that promoter hypermethylation of RASSF1A and HIC1 genes play a role in resistance of GCT, while the transcriptional inactivation of MGMT by epigenetic alterations confer exquisite sensitivity to cisplatin. Cisplatin 230-239 Ras association domain family member 1 Homo sapiens 68-75 15705880-9 2005 However, CIMP was significantly associated with methylation of promoter CGIs of the RASSF1A and BLU tumor suppressor genes. Cyclic IMP 9-13 Ras association domain family member 1 Homo sapiens 84-91 15612586-1 2004 The methylation level of 13 CpG-dinucleotides in the promoter region of the putative tumor suppressor gene RASSF1A (3p21.31) was analyzed in HPV-positive squamous cell carcinomas of cervix using methyl-sensitive restriction endonuclease analysis followed by PCR. cytidylyl-3'-5'-guanosine 28-45 Ras association domain family member 1 Homo sapiens 107-114 15208682-3 2004 Here we investigated another main isoform, RASSF1C, and compared it with RASSF1A in the gene inactivation test (GIT), based on a tetracycline regulation system. Tetracycline 129-141 Ras association domain family member 1 Homo sapiens 73-80 15109305-6 2004 Co-expression of RASSF1A, RASSF1C, NORE1A and NORE1B with MST1 markedly suppresses MST1(Thr183) phosphorylation in vivo and abolishes the ability of MST1 to undergo Mg-ATP-mediated autoactivation in vitro; direct addition of purified NORE1A in vitro also inhibits MST1 activation. Adenosine Triphosphate 165-171 Ras association domain family member 1 Homo sapiens 17-24 14586413-7 2003 RASSF1A was re-expressed in all methylated cell lines after treatment with the demethylating agent 5-aza-2"-deoxycytidine. Decitabine 99-121 Ras association domain family member 1 Homo sapiens 0-7 14961576-11 2004 Treatment of the cell lines with 5-aza-2"-deoxycytidine and trichostatin A resulted in demethylation of the RASSF1A promoter and re-expression of RASSF1A transcripts. Decitabine 33-55 Ras association domain family member 1 Homo sapiens 108-115 14961576-11 2004 Treatment of the cell lines with 5-aza-2"-deoxycytidine and trichostatin A resulted in demethylation of the RASSF1A promoter and re-expression of RASSF1A transcripts. Decitabine 33-55 Ras association domain family member 1 Homo sapiens 146-153 14961576-11 2004 Treatment of the cell lines with 5-aza-2"-deoxycytidine and trichostatin A resulted in demethylation of the RASSF1A promoter and re-expression of RASSF1A transcripts. trichostatin A 60-74 Ras association domain family member 1 Homo sapiens 108-115 14961576-11 2004 Treatment of the cell lines with 5-aza-2"-deoxycytidine and trichostatin A resulted in demethylation of the RASSF1A promoter and re-expression of RASSF1A transcripts. trichostatin A 60-74 Ras association domain family member 1 Homo sapiens 146-153 14961078-4 2004 Methylation-specific PCR and bisulfite genomic sequencing revealed that the RASSF1A promoter was hypermethylated in all four RASSF1A-nonexpressing cell lines. hydrogen sulfite 29-38 Ras association domain family member 1 Homo sapiens 76-83 14961078-5 2004 5-aza-2"-deoxycytidine treatment resulted in demethylation of the promoter and RASSF1A expression in these lines. Decitabine 0-22 Ras association domain family member 1 Homo sapiens 79-86 14500366-5 2003 Initially we demonstrated that transient expression of RASSF1A into the NSCLC cell line A549 induced G(1) cell cycle arrest, as measured by propidium iodide staining. Propidium 140-156 Ras association domain family member 1 Homo sapiens 55-62 14559801-5 2003 The methylation-specific oligonucleotide data indicate that the majority of test samples show widespread methylation in the first exon of RASSF1A. Oligonucleotides 25-40 Ras association domain family member 1 Homo sapiens 138-145 14559801-8 2003 Functional analysis indicates that increased density of RASSF1A promoter methylation is associated with altered chromatin, marked by a depletion of acetylated histones and methylated histone 3-lysine 4 and an enrichment of methylated histone 3-lysine 9 in the studied area. 3-lysine 191-199 Ras association domain family member 1 Homo sapiens 56-63 14559801-8 2003 Functional analysis indicates that increased density of RASSF1A promoter methylation is associated with altered chromatin, marked by a depletion of acetylated histones and methylated histone 3-lysine 4 and an enrichment of methylated histone 3-lysine 9 in the studied area. 3-lysine 242-250 Ras association domain family member 1 Homo sapiens 56-63 14506151-5 2003 5-aza-2-deoxycytidine was used to demethylate the RASSF1A promoter in cell lines. Decitabine 0-21 Ras association domain family member 1 Homo sapiens 50-57 14500366-6 2003 Furthermore, annexin-V staining showed that RASSF1A-expressing cells had an increased sensitivity to staurosporine-induced apoptosis. Staurosporine 101-114 Ras association domain family member 1 Homo sapiens 44-51 14506151-8 2003 After treatment with 5-aza-2-deoxycytidine, re-expression and demethylation of RASSF1A gene were detected in cell lines with promoter hypermethylation. Decitabine 21-42 Ras association domain family member 1 Homo sapiens 79-86 12912945-10 2003 Real-time methylation-specific PCR system was used for the detection and quantitation of the bisulfite-converted methylated version of the RASSF1A promoter region. hydrogen sulfite 93-102 Ras association domain family member 1 Homo sapiens 139-146 12960125-2 2003 In this study, we analyzed the methylation status of the promoter region of RASSF1A using bisulfite sequencing and PCR-RFLP in four liver cancer cell lines (Hep3B, HepG(2), SK-HEP-1, and Huh-7) and a cohort of 43 hepatitis B virus-associated hepatocellular carcinoma (HCC) tissues and their corresponding nontumor tissue specimens. hydrogen sulfite 90-99 Ras association domain family member 1 Homo sapiens 76-83 12960125-5 2003 Treatment with the DNA methylation inhibitor 5-aza-2"-deoxycytidine reactivated the expression of RASSF1A in the Hep3B and HepG2 cells. Decitabine 45-67 Ras association domain family member 1 Homo sapiens 98-105 12670917-11 2003 RASSF1A transcripts could be reexpressed in cell lines after treatment with 5"-aza-2"-deoxycytidine. Decitabine 76-99 Ras association domain family member 1 Homo sapiens 0-7 12792742-4 2003 Treatment of these cell lines with the DNA methylation inhibitor 5-aza-2"-deoxycytidine reactivated the transcription of RASSF1A, but not that of RASSF1B or RASSF1C. Decitabine 65-87 Ras association domain family member 1 Homo sapiens 121-128 12802288-4 2003 In seven out of eight pancreas cancer cell lines, RASSF1A was silenced and was retranscribed after treatment with 5-aza-2"-deoxycytidine. Decitabine 114-136 Ras association domain family member 1 Homo sapiens 50-57 12384556-3 2002 Hypermethylation was associated with epigenetic silencing of RASSF1A transcription in medulloblastoma cell lines, and RASSF1A expression in these lines was restored after treatment with the DNA-methyltransferase inhibitor 5-aza-2"-deoxycytidine. Decitabine 222-244 Ras association domain family member 1 Homo sapiens 61-68 12527916-6 2003 In our breast cancer trios, RASSF1A promoter hypermethylation was detected in 65% of invasive cancers, in 42% of corresponding DCIS but in none of the normal breast samples. dcis 127-131 Ras association domain family member 1 Homo sapiens 28-35 12448005-5 2002 Bisulfite-modified DNA was examined for gene promoter hypermethylation in DAP-kinase, E-cadherin, GSTP1, p14, p15, p16, RASSF1A and hMLH1 by methylation-specific-PCR. hydrogen sulfite 0-9 Ras association domain family member 1 Homo sapiens 120-127 12399230-6 2002 Using bisulphite modification followed by methyl-specific PCR, a high incidence of methylated RASSF1A promoter region was detected in our current series (9/13 cases; 69%). hydrogen sulfite 6-16 Ras association domain family member 1 Homo sapiens 94-101 12384556-3 2002 Hypermethylation was associated with epigenetic silencing of RASSF1A transcription in medulloblastoma cell lines, and RASSF1A expression in these lines was restored after treatment with the DNA-methyltransferase inhibitor 5-aza-2"-deoxycytidine. Decitabine 222-244 Ras association domain family member 1 Homo sapiens 118-125 12360410-8 2002 Expression of RASSF1A was restored with 5-aza-2"-deoxycytidine, a DNA methylation inhibitor. Decitabine 40-62 Ras association domain family member 1 Homo sapiens 14-21 11585730-4 2001 Bisulfite DNA sequencing analysis revealed that the CpG island in the RASSF1A promoter is hypermethylated in all RASSF1A-nonexpressing cell lines. hydrogen sulfite 0-9 Ras association domain family member 1 Homo sapiens 70-77 11709729-8 2001 In two neuroblastoma cell lines, methylation of RASSF1A correlated with loss of RASSF1A expression and RASSF1A expression was restored after treatment with the demethylating agent 5-azacytidine. Azacitidine 180-193 Ras association domain family member 1 Homo sapiens 48-55 11709729-8 2001 In two neuroblastoma cell lines, methylation of RASSF1A correlated with loss of RASSF1A expression and RASSF1A expression was restored after treatment with the demethylating agent 5-azacytidine. Azacitidine 180-193 Ras association domain family member 1 Homo sapiens 80-87 11709729-8 2001 In two neuroblastoma cell lines, methylation of RASSF1A correlated with loss of RASSF1A expression and RASSF1A expression was restored after treatment with the demethylating agent 5-azacytidine. Azacitidine 180-193 Ras association domain family member 1 Homo sapiens 80-87 12097277-6 2002 Treatment of these cell lines with the DNA methylation inhibitor 5-aza-2"-deoxycytidine reactivated the transcription of RASSF1A. Decitabine 65-87 Ras association domain family member 1 Homo sapiens 121-128 11585766-8 2001 In CC-RCC cell lines, RASSF1A methylation was associated with silencing of RASSF1A expression and restoration of expression after treatment with 5"-azacytidine. Azacitidine 145-159 Ras association domain family member 1 Homo sapiens 22-29 11585730-4 2001 Bisulfite DNA sequencing analysis revealed that the CpG island in the RASSF1A promoter is hypermethylated in all RASSF1A-nonexpressing cell lines. hydrogen sulfite 0-9 Ras association domain family member 1 Homo sapiens 113-120 11585730-5 2001 In addition, both RASSF1A and RASSF1B were re-expressed by treatment with the demethylating agent 5-aza-2"-deoxycytidine. Decitabine 98-120 Ras association domain family member 1 Homo sapiens 18-25 11559536-8 2001 Expression of RASSF1A and RASSF1B was reactivated in all nonexpressor cell lines by treatment with the demethylating agent 5-aza-2"-deoxycytidine. Decitabine 123-145 Ras association domain family member 1 Homo sapiens 14-21 11559536-9 2001 Bisulfite DNA sequencing analysis revealed that aberrant hypermethylation at the CpG island in the RASSF1A promoter is strongly associated with the loss of RASSF1A expression in cell lines and uncultured primary tumors. hydrogen sulfite 0-9 Ras association domain family member 1 Homo sapiens 99-106 11559536-9 2001 Bisulfite DNA sequencing analysis revealed that aberrant hypermethylation at the CpG island in the RASSF1A promoter is strongly associated with the loss of RASSF1A expression in cell lines and uncultured primary tumors. hydrogen sulfite 0-9 Ras association domain family member 1 Homo sapiens 156-163 11306494-5 2001 Treatment with the DNA methylation inhibitor 5-aza-2"-deoxycytidine reactivated the expression of RASSF1A. Decitabine 45-67 Ras association domain family member 1 Homo sapiens 98-105 11390984-8 2001 RASSF1A expression was reactivated after treatment with 5-aza-2"-deoxycytidine. Decitabine 56-78 Ras association domain family member 1 Homo sapiens 0-7 10998413-6 2000 We now show that RASSF1 binds Ras in a GTP-dependent manner, both in vivo and directly in vitro. Guanosine Triphosphate 39-42 Ras association domain family member 1 Homo sapiens 17-23